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Leishmanization is the inoculation of live Leishmania into the host to vaccinate
against subsequent infections. This approach has been largely discontinued due to
safety concerns. We have previously shown that combining CD40L with Leishma-
nia antigen preferentially induces a type 1 immune response and provides some pro-
tection to vaccinated mice. In the present study, we developed transgenic L. major
which express and secrete the extracellular portion of CD40L (L. major CD40LE).
We hypothesized that these organisms would be less virulent but more immuno-
genic than wild-type organisms, and therefore be more effective at leishmanization.
Transgenic parasites expressing CD40L mRNA and protein were developed. These
parasites had similar growth characteristics to wild-type organisms. Susceptible
BALB/c mice infected with these parasites developed significantly smaller lesions
containing fewer parasites than animals infected with wild-type organisms. Infec-
tion of C57BL/6 CD40L-/- mice with transgenic L. major resulted in significantly
smaller lesions than infection with wild-type L. major, indicating in vivo biologi-
cal activity of the transgenic protein. Infection of resistant C57BL/6 mice with low
doses of transgenic parasites induced a significant amount of protection against sub-
sequent high dose infection with wild-type organisms. These results demonstrate
that transgenic organisms expressing CD40L are less virulent than wild-type organ-
isms while retaining full immunogenicity. The implications of this study are that
parasites expressing immune-modulatory molecules may be improved alternatives
to traditional leishmanization.
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This dissertation is dedicated to my family, especially to my late grandfather. He
got me started in science by getting me a microscope. Then, when I called to say
I’d joined the Mosser lab and would be working on Leishmania, his first question
was, “Is that a trypanosome?”
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The immune system is divided into two components, innate and adaptive im-
munity. Innate immunity is the body’s first line of defense against invasion by
pathogens. It was evolutionally developed prior to adaptive immunity, and virtu-
ally every multi-cellular organism has some form of innate immunity [1–5]. In-
nate immunity utilizes a variety of mechanisms to protect the host. First, contact
with possible pathogens is minimized through barriers such as skin and mucous
membranes. Mucus traps potential pathogens and cilia expel mucus from the body,
preventing attachment of potential pathogens. Body fluids contain anti-microbial
proteins including defensins and complement that help to destroy microbes [1].
The innate immune system also contains cells that patrol the body for infection,
including macrophages and dendritic cells. These cells can ingest material from
their surroundings which initiates several different pathways. They can directly
destroy microbes, or present antigen to alert the adaptive immune system. First,
however, these cells must be able to distinguish self from non-self. The innate im-
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mune system uses pattern recognition receptors (PRRs) that identify certain highly
conserved structures found on numerous pathogens. These highly conserved struc-
tures are referred to as pathogen-associated molecular patterns (PAMPs) and in-
clude lipopolysaccharide (LPS), peptidoglycan, CpG DNA, double stranded RNA,
and many others. These PAMPs are not produced by the host, so their presence
signifies an infection. Often, these microbial products are essential for pathogen
survival, which means loss or mutation of these structures is unlikely. Thus, recog-
nition of essential structures reduces the chance of the pathogen simply changing
the structure to evade innate immunity [4]. There are several types of PRRs, in-
cluding Toll-like receptors (TLRs), Nods/NALPs, mannose receptors, and scav-
enger receptors [5]. These receptors have different functions. Mannose receptors
and scavenger receptors improve phagocytosis, allowing microbes to be taken up
and destroyed. Toll-like receptors and Nods/NALPs, however, provide signaling to
alert the cell that the material being ingested is foreign.
Toll-like receptors are membrane associated receptors present on phagocytes
and other cells that lead to activation of the innate immune system. Toll was
first discovered as a gene having a role in dorsal-ventral polarity in Drosophila
melanogaster by Nusslein-Volhard in 1985 [6]. Its role in immunity was later dis-
covered by Lemaitre in 1996 [7]. Lemaitre showed that a mutation in Toll led to
an inability to fight off fungal infection. A mutation in imd was shown to be re-
sponsible for immunity to bacterial infection [7]. Eleven different TLRs have been
identified to date in humans [8]. These are defined by a common TIR domain in the
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cytoplasmic region [9]. TLRs are capable of recognizing a wide variety of pathogen
patterns. For example, TLR4 recognizes bacterial lipopolysaccharide (LPS), while
TLR9 recognizes bacterial DNA containing unmethylated CpG motifs, and TLR5
recognizes bacterial flagellin [10]. Other TLRs recognize peptidoglycan (TLR2),
fungal cell wall (TLR6), dsRNA (TLR3), and ssRNA (TLR7) [10–12]. In addition,
TLRs can combine to increase specificity. TLR2 can dimerize with TLR6 or TLR1
to increase specificity and induce signaling [10]. Ligation of toll-like receptors
leads to signaling through adaptor molecules that induces inflammatory cytokines,
interferon inducible genes, and maturation of dendritic cells [10, 13]. Different
TLRs use different combinations of adaptor molecules. For example, TLR4 uses
both MyD88 dependent signaling and a MyD88 independent mechanism to induce
inflammatory cytokines, while TLR2 only uses MyD88 dependent signaling to in-
duce these cytokines [13]. The different pathways induced through different TLRs
illustrate how different TLRs could induce specific responses to a pathogen.
Nods/NALPs belong to a family of intracellular proteins containing neucleotide
binding domains and leucine rich repeats (NBS-LRR)[14]. These molecules are
differentiated by N-terminal effector motifs. Nods have caspase-activating and re-
cruitment domains (CARD), while NALPs have an N-terminal pyrin domain (PYD)
[14]. Nod1 has been shown to bind procaspase-9 and RICK, and induce apoptosis
and NF-κB [15]. It has been established that Nod1 recognizes gram-negative bac-
terial peptidoglycan components and is important in the innate response to these
organisms [16, 17]. Nod 2 has been shown to recognize muramyl dipeptide (MDP),
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the minimal active peptidoglycan motif present in both gram-positive and gram-
negative bacteria [18].
In addition to these receptors, others recognize self-generated molecules that
enhance phagocytosis, like complement receptors. Complement proteins deposit on
pathogen surfaces, allowing for recognition by complement receptors and improved
phagocytosis or direct pathogen lysis. When the cells of the innate immune system
encounter a pathogen, they do their best to destroy it through nitric oxide (NO),
reactive oxygen (ROI), acidic environments, and proteases. If innate immunity fails
to eliminate the intruder, the innate immune cells fulfill one critical function: to
alert the adaptive immune reponse [1].
Macrophages
Macrophages play an important role in innate immunity and provide antigen
interaction and co-stimulation to adaptive immune cells. These cells are efficient
at phagocytosis, and their primary function is to destroy ingested material in their
highly acidic phagolysosomes. Upon phagocytosis, macrophages also produce a
variety of other microbicidal products including nitric oxide, superoxide, and hy-
drogen peroxide [19]. They are present in the periphery and in virtually all endothe-
lial surfaces, and thus have access to entering pathogens. In addition to their di-
rect destruction of pathogens, they serve another important function. Macrophages
are a part of an elite group of cells known as the professional antigen presenting
cells (APCs), which are known for their ability to present antigen to CD4+ T cells
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through their expression of the major histocompatibility complex (MHC) class II.
Dendritic cells and B cells make up the other members of the professional APCs.
These cells serve the critical function of activating adaptive immunity, thus linking
innate and adaptive immunity.
To efficiently activate T cells, macrophages must express MHC class II with
antigen and a second signal or “danger” signal to alert T cells that the antigen is
from a foreign body (Figure 1)[19]. Examples of danger signals (also referred to as
co-stimulation) include CD40, CD80, and CD86. Resting macrophages express few
MHC class II molecules and co-stimulatory molecules. Macrophages must undergo
an activation process due to their encounter with a pathogen to express the danger
signal that will induce T cell activation. In addition to these cell surface markers,
macrophage activation can lead to cytokine release that assists in T cell activation
or activation of neighboring macrophages [19].
Macrophage activation is a complex process with multiple stimuli resulting in
different activation patterns and subsequent influence over the character of the adap-
tive immune response. To date three major classifications of macrophage activation
have been identified that that can be reliably reproduced in vitro. The first type of
macrophage activation to be discovered is now known as classical activation. This is
characterized by activation through IFN-γ and TNF-α or an inducer of TNF-α such
as signaling through Toll-like receptors. This stimulation induces NF-κB translo-
cation, and secretion of IL-12 and TNF-α, and many other cytokines as well as up-
regulation of co-stimulatory molecules CD40, CD86, and CD80. Classically acti-
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Figure 1: Activation of adaptive immunity through antigen presentation.
Adapted from Kapsenberg [20]. Macrophages and DCs identify pathogens through
PRRs. Recognition of PAMPs leads to improved antigen presentation to T cells
and up-regulation of co-stimulatory molecules like CD28. Upon interacting with
a naı̈ve T cell specific for the pathogen antigen, APCs initiate T cell activation
through co-stimulation and secreted factors that instruct the T cell on the type of
response to make. T cells then differentiate into effector cells of the Th1 or Th2
variety.
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vated macrophages also produce nitric oxide and reactive oxygen species [21]. The
second type of activation was termed “alternative” activation, and is accomplished
through exposure of macrophages to the Th2 cytokines IL-4 or IL-13. These cells
can be characterized by high arginase expression, expression of FIZZ-1 and YM-1
[22], and the expression of many components of the extracellular matrix [21, 23].
Alternatively activated macrophages do not produce NO, unlike their classically ac-
tivated counterparts [23]. Thus they are impaired in their ability to kill pathogens.
Although they do express some MHC class II, they have been shown to be poor
antigen presenting cells unable to induce high levels of T cell proliferation [23].
It is thought that these cells play a role in dampening of the acute inflammatory
response and assisting with wound-healing [21].
The third type of macrophage activation is termed “type II” activation [24]. In
this type of activation, TLR signals are coupled with FcγR ligation. Type II acti-
vation results in down-regulation of IL-12, and up-regulation of IL-10 [25]. These
macrophages have been shown to induce a Th2, or humoral adaptive immune re-
sponse [26]. When type II macrophages were used as antigen presenting cells,
T cells were stimulated to secrete IL-4, a hallmark cytokine of the humoral re-
sponse. In contrast, when classically activated macrophages were used as APCs,
T cells expressed IFN-γ [26]. Immunization of mice with type II macrophages led
to a humoral response characterized by high levels of IgG1, indicating that these
macrophges are sufficient to activate humoral immunity and induce class switch-
ing [24]. These macrophages play an important role in amplifying the humoral
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response in vivo, and have been shown in some cases, for example in leishmaniasis,
to exacerbate disease by skewing towards an inappropriate response [27].
Dendritic Cells
Dendritic cells (DCs) are the most potent of all the professional APCs, and are
particularly adept at priming naı̈ve T cells [2, 3]. They are derived from precursors
in the bone marrow, and migrate to the periphery where they take up antigen. When
they are activated by a pathogen they return to lymph nodes where they prime T
cells to respond to the infection.
DCs are derived from a number of different bone marrow precursors. They leave
the bone marrow and travel the blood and lymphatics as immature dendritic cells.
These immature DCs migrate to tissue, where they are efficient phagocytes, sam-
pling the surrounding area for infection. They mature when activated, up-regulating
co-stimulatory molecules (CD40, CD80, CD86) and stably expressing MHC class
II complexes on the surface. They lose their phagocytic capabilities, but become
professional antigen presenting cells [2, 28]. They also alter their chemokine re-
ceptor expression profile, down-regulating receptors that would keep them in the
periphery and up-regulating CCR7 to initiate migration to the lymph nodes [29].
All DCs follow this general maturation progression, however all DCs are not
identical. Different DC subsets exist, and currently there is much debate as to the
importance of these different subsets. Defining the subsets and their function is a
complex study. The cells are relatively rare in vivo, which makes them difficult to
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isolate and study. Ex vivo studies are complicated by the tendency of DCs to sponta-
neously mature during handling, drastically altering their phenotype [30]. Several
categories of DCs have been identified to date. These include pre-DCs (a subset
of which are plasmacytoid DCs), conventional DCs (further split into migratory
and lymphoid-resident), and inflammatory DCs (i.e. Tip DCs that can occur dur-
ing disease states) [31]. Plasmacytoid DCs are known for their ability to produce
type 1 interferons and induce antiviral immunity. Conventional migratory DCs are
those that patrol the periphery for foreign antigen and mature to report to the lymph
nodes. Lymphoid-tissue-resident DCs sample lymphoid organs for foreign material
and can be further subdivided into many subsets, including splenic and thymic DCs.
Inflammatory DCs are not normally present in the steady state and are induced fol-
lowing antigen encounter. For example, Tip DCs are inflammatory DCs designated
by their ability to produce TNF-α and iNOS in response to infection [31]. It is still
unclear whether the different subsets are actually different populations or represent
different maturation states of the same population [32].
There is also debate over whether the different subsets respond to specific kinds
of pathogens, or if DCs of different subsets are flexible enough to respond to many
different pathogens. Originally, it was thought that different subsets were pre-
programmed to respond to either Th1 or Th2 stimuli [20]. This was based on the
different TLR profiles of human DC subsets. Initial evidence indicated that CD8α+
DCs primarily induce a Th1 response, while CD8α- DCs primarily induce a Th2
response [30]. However, it seems that DCs should be able to discriminate among
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various pathogens to be most effective. Recent literature seems to suggest that
DCs are flexible, and may respond to a variety of pathogens, regardless of subset
[20, 30, 33, 34]. For example, de Jong et al. found that immature DCs receiving
antigen from Shistosoma mansoni matured as a DC2 phenotype, capable of induc-
ing a stable Th2 response from T cells. Immature DCs receiving antigen from the
intracellular bacterium Bordetella pertussis matured in a DC1 phenotype, generat-
ing a Th1 response from T cells [33]. In addition, previous work in our lab has
shown that the stimulation of immature bone-marrow derived DCs (BMDCs) with
the TLR ligands LPS and CpG DNA resulted in a Th1 response from T cells with
the production of IFN-γ from these cells [35]. When immature BMDCs were stim-
ulated with immune complexes in addition to LPS and CpG DNA, T cell responses
were skewed towards a Th2 response, with IL-4 detected instead of IFN-γ. Immu-
nization of mice to ovalbumin through transfer of BMDCs activated with immune
complexes induced high IgG1 antibody titers indicative of an in vivo Th2 response.
When TLR ligands were used without immune complexes as stimulation for cell
transfer, little antibody response was detected [35]. These data would support the
hypothesis that DCs are able to respond to the maturation stimuli received to induce
an appropriate adaptive immune response. The literature surrounding this topic is
complex and the underlying theories are still being challenged. Much work still
needs to be done to determine the role of the different DC subsets in regulating
and activating the immune system, however, the literature is starting to indicate that
the stimulus a DC receives is the most important determinant of fate and thus can
10




When the innate immune system is unable to rid the host of an invading or-
ganism, adaptive immunity is activated. Adaptive immunity can be differentiated
from innate immunity based upon the cells involved, the receptors used, and the
specificity of the response. As previously mentioned, innate immune cells recog-
nize patterns or classes of molecules. These receptors are encoded in the germline,
and all cells that express a receptor have the same specificity [1, 4, 5]. The cells of
the adaptive immune system are far more specific in their response. The adaptive
response is composed of two major cell types: B and T cells. Each naı̈ve cell has a
unique receptor generated through random gene segment recombination at the loci
encoding the BCR or TCR to allow for exquisite specificity in pathogen antigen
recognition. This allows for incredible diversity in a large repertoire of cells with
the potential to respond to virtually all pathogens. The receptors on B cells recog-
nize particulate antigen, and these cells are responsible for producing antibody. T
cells recognize antigen in the context of MHC expressed on the surface of an APC
or other cell. There are two major classes of T cell, CD4+ T cells and CD8+ T
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cells. CD4+ T cells recognize antigen in the context of MHC class II present on
APCs. CD8+ T cells, or cytotoxic T cells (CTLs) recognize antigen in MHC class
I molecules present on all cells in the body.
There are three major subsets of mature B and T cells: naı̈ve, effector, and mem-
ory cells. Naı̈ve cells are mature cells that have yet to encounter antigen. Effector
cells are cells that have recently encountered antigen and have been induced to pro-
liferate and act upon other cells to eradicate the pathogen. The differentiation from
naı̈ve to effector cell is the primary immune response. During this reponse, mem-
ory cells are generated that can provide protection against subsequent challenge
with the same pathogen.
Adaptive immunity systematically and specifically rids the body of pathogens.
However, adaptive immunity must initially be activated by innate immunity through
antigen presentation and co-stimulation typically provided by macrophages and
DCs. Naı̈ve B and T cells that receive antigen and co-stimulation are signaled to
undergo clonal expansion. This is a process that allows generation of an expanded
population of cells with specificity for the pathogen antigen. During clonal expan-
sion, cells develop into effector cells or memory cells. Once activated, the adaptive
immune system develops one of two general responses: a cell-mediated (Th1) or
humoral (Th2) response . Th1 responses are generally mounted in response to intra-
cellular pathogens, while Th2 responses are generated to extracellular pathogens.
The most important component of adaptive immunity is memory. This function is
unique to adaptive immunity. The mechanism of memory cell generation is poorly
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understood, but these cells provide a rapid, ready response upon re-infection with a
pathogen, and can prevent illness. This is why once an adaptive immune response
has been generated to a pathogen, an individual is usually immune to a second
exposure [19].
T cells
T cells originate in the bone marrow, and very early in development lymphoid
progenitors travel to the thymus, where they complete development into T cells.
Early in development, cells are “double negative,” (DN) meaning that they do not
yet express CD4 or CD8. T cells that undergo successful rearrangement of the
TCRβ chain become “double positive” cells, characterized by their expression of
both CD4 and CD8 and enter the late phase of T cell development. Double posi-
tive cells must undergo rigorous selection before maturing into single positive naı̈ve
cells that are permitted to leave the thymus. Double positive cells continue to re-
arrange their TCR-α chain until a functional receptor is formed that recognizes
self-MHC expressed by thymic epithelial cells. 90% of cells are unable to produce
a functional TCR capable of recognizing self-MHC and die by neglect. Approx-
imately 5% of cells will generate a TCR that reacts strongly to self-MHC. These
cells are deleted through apoptosis in a process called negative selection [36]. The
mechanism of negative selection is not fully understood, but it has been proposed
that the strength of signal through the TCR determines the fate of the cell, whether
it is survival or death. Cells with low affinity for self-MHC are permitted to mature
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into single positive cells (positive selection), while those with high affinity for self-
MHC are deleted [37]. The successfully selected single positive cells are permitted
to leave the thymus and circulate to the periphery and secondary lymphoid organs
where they may encounter antigen.
CD8+ cells are also referred to as cytoxic T lymphocytes, or CTLs. They recog-
nize antigen presented in the context of MHC class I molecules present on all cells
in the body. CTL activation is especially important in the case of viral infection,
where virus proteins can be expressed in the context of MHC class I on different
cell types. CTLs must receive two signals for activation, antigen stimulation and co-
stimulation, for example IL-2 [38]. Once a CTL becomes activated, it targets cells
expressing MHC class I containing specific antigen and directs killing of target cells
through the release of perforin from preformed cytolytic granules or Fas-Fas ligand
interactions. These cells also produce IFN-γ that can promote macrophage activa-
tion and Th1 responses, but these levels are typically lower than those of CD4+ Th1
cells [39].
CD4+ T helper cells were originally thought to be a single population of cells.
However, many subsets of CD4+ cells with different functions have been identified
to date. Figure 2 illustrates several major subsets with cytokines demonstrated to
be relevant in their development and the signature cytokine they produce. Tada et
al. in 1978 first provided evidence that two distinct subsets of T helper cells ex-
isted, separable by passage through a nylon wool column [40]. They termed those
cells found to be nonadherent to nylon “Th1”, and those cells found to be adher-
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Figure 2: Overview of CD4+ T cell subsets.
Naı̈ve CD4+ T cells differientate into many types of effector cells upon encoun-
tering antigen. Th1 and Th2 cells drive cell-mediated and humoral immunity re-
spectively. IL-12 and IFNγ have been shown to give rise to Th1 cells, and IL-4 can
induce differentiation of Th2 cells. Th1 cells primarily produce IFN-γ, which helps
to activate macrophages. Th2 cells produce IL-4, among other cytokines that drive
antibody production and class switching. Th17 cells have been shown to be in-
volved in autoimmunity and some cancers, and arise from TGF-β and IL-6 signals.
IL-23 can act on activated or memory Th17 cells. Th17 cells produce IL-17, which
can act on macrophages to induce Il-1β and TNF-α. Th3 cells arise in the presence
of TGF-β and produce TGF-β. Tr1 cells arise in the presence of high IL-10, and
produce high levels of IL-10. nTregs are generated during negative selection in the
thymus.
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ent to nylon “Th2”. Mosmann et al. in 1986 followed Tada’s nomenclature and
further defined these two subsets by differential expression of lymphokine proteins
[41]. They found that Th1 cells expressed IL-2, IFN-γ, and IL-3, while Th2 cells
were found to produce B cell stimulating factor 1 (BSF-1, later known as IL-4) and
enhanced IgG1 and IgE production. Th1 cells were shown to be responsible for de-
layed type hypersensitivity (DTH) reactions, while Th2 cells were unable to induce
DTH responses [42]. Further characterization of these two subsets showed that Th1
cells produce IFN-γ, IL-2, and lymphotoxin, while Th2 cells produce IL-4 and IL-5
[41]. Th1 cells are important in intracellular infections, such as leishmaniasis [43],
while Th2 cells play a role in extracellular infections. Exactly how naı̈ve T cells
are instructed to become Th1 or Th2 cells is still not fully understood, but several
cytokines and methods of stimulation have been shown to preferentially induce one
response over the other. It has been shown that IFN-γ [44] or IL-12 [45, 46] can
induce Th1 cell development, while IL-4 can promote Th2 cell development. In
addition, the stimulus received by antigen presenting cells can play a role in naı̈ve
T cell instruction. LPS induces IL-12 from macrophages, promoting Th1 cells,
while coupling LPS with FcγR stimulation causes macrophages to produce IL-10
and promote Th2 cell development [25].
In addition to Th1 and Th2 cells, CD4+ suppressor T cells or regulatory T cells
(Treg) have been described. Treg cells have been shown to be composed of many
subsets. Three of the populations receiving the most attention are “natural” Tregs,
Tr1 cells, and Th3 cells. Tregs were first described in a series of elegant experi-
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ments that demonstrated the ability of a population of CD4+CD25+ cells to control
autoimmunity [47]. When CD25+ cells were depleted, mice developed severe au-
toimmune disease. Co-transfer of CD25+ cells was able to prevent autoimmunity,
demonstrating that this population was responsible for maintaining self-tolerance.
Naturally occurring Tregs (nTreg) are defined by their expression of CD25
and Foxp3. Fontenot et al. demonstrated that Foxp3 expression was specific to
CD4+CD25+ T cells [48]. Mice deficient in Foxp3 developed lethal autoimmune
disease that could be treated early on with CD25+ cell transfer and prevent lethal-
ity. Ectopic expression of Foxp3 was also shown to confer suppressor function
onto CD4+CD25- cells, indicating the important role of this transcription factor in
development of a suppressor population. Natural Tregs develop in the thymus dur-
ing negative selection, and act in a cell-contact dependent, cytokine independent
manner [49, 50].
Tr1 cells are induced from naı̈ve CD4+ cells by high IL-10 levels [51]. These
cells require stimulation through the TCR in addition to IL-10, and then are able
to induce bystander suppression through IL-10 and TGF-β secretion [52]. The pri-
mary role of these cells is thought to be in gut tolerance. IL-10 knockout mice have
been shown to be prone to inflammatory bowel disease that is prevented through
adoptive transfer of IL-10 competent CD45RBlow cells [53].
Th3 cells were first discovered in studies of oral tolerance [54]. These cells
require TCR stimulation and TGF-β for development [55]. They secrete TGF-β,
IL-4, and IL-10, and promote IgA production. They are generated in gut associated
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lymphoid tissue in the presence of high levels of TGF-β primarily after ingestion
of foreign antigen. They also express CTLA-4 on their surface, and stimulation
through CTLA-4 results in TGF-β secretion. Upon stimulation with TGF-β, Th3
cells upregulate CD25 and Foxp3, however these cells differ from natural Tregs
through the TGF-β mechanism of suppression rather than the natural Treg cell-
contact dependent method [56].
Recently, a new subset of CD4+ T cells was discovered that are characterized
by their production of IL-17 [57]. Thus, these cells have been termed Th17 cells.
The story of this subset begins with the discovery of IL-23, a cytokine that shares
the p40 subunit with IL-12, but instead of the p35 subunit, has a p19 subunit [58].
This cytokine was found to be expressed by activated macrophages and DCs and
to act upon T cells. The common p40 subunit with IL-12 threw into question the
use of p40 knockout systems to study the role of IL-12 in disease. Indeed, study
of experimental autoimmune encephalomyelitis (EAE) revealed that IL-23, not IL-
12 (as previously thought) was responsible for disease progression [59]. IL-23
was shown to drive an IL-17 producing T cell population that was demonstrated to
have encephalogenic properties when adoptively transferred [57]. In addition, mice
deficient in the p19 subunit of IL-23 were found to lack the population of T cells
expressing IL-17 [60].
Th17 cells has recently been shown to be generated through TGF-β and IL-6
stimulation of naı̈ve T cells, and it has been established that the effects of IL-23
are primarily on memory or activated T cells [61]. Some Tregs are known to be
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generated through exposure to TGF-β, and it was demonstrated that the addition of
IL-6 was sufficient to exclude Treg development and drive Th17 developent. IL-
17 has been shown to induce IL-1β and TNF-α from human macrophages among
other cytokines [62], and these cells have been implicated in a number of autoim-
mune disorders some of which include multiple sclerosis [63], lupus [64], and en-
cephalomyelitis [59] through elevation of IL-17 levels [63, 64]. IL-23 has also
been demonstrated to be elevated in tumors [59] and to provide limited resistance
to toxoplasmosis in the absence of IL-12 [65].
Humoral Immunity
Many pathogens that cause infections replicate in the extracellular spaces of
the body. These extracellular spaces are protected by humoral immunity. In this
form of adaptive immunity, naı̈ve mature B cells are activated to produce antibody.
These antibodies contribute to the destruction of invading pathogens in a variety
of ways (Figure 3). Antibodies can neutralize pathogens by binding molecules
required for invasion of tissues and toxin action. They also target pathogens for
uptake by phagocytic cells either directly by Fc receptors, or indirectly by activating
the classical pathway of complement (Figure 3). Complement activation opsonizes
microbes for phagocytosis and can also induce direct killing through membrane
attack complex (MAC) pore formation [19].
Antibodies from different subtypes have different effector functions in humoral
immunity [19]. IgM exists as both a membrane bound form and a secreted form.
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Figure 3: B cell effector functions.
Adapted from Janeway [19]. When activated, some B cells differentiate in to ef-
fector B cells, or plasma cells. Plasma cells secrete antibody that mediate three
major mechanisms of pathogen eradication: neutralization, opsonization, and com-
plement activation. Neutralization prevents pathogens from invading, opsonization
targets pathogens for efficient phagocytosis, and complement activation leads to
direct pathogen killing and improved phagocytosis.
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The secreted form of IgM forms pentamers and is primarily involved in complement
activation. IgA molecules form monomers or dimers, and are found at mucosal
surfaces where their major function is to neutralize pathogens and prevent pathogen
attachment to mucosal surfaces. IgG antibody is usually of higher affinity than
IgM antibodies and has many functions. IgG can neutralize toxins, viruses, and
bacteria, opsonize them for phagocytosis and activate the complement system. In
mice, IgG1 antibodies are associated with type 2 responses, while IgG2a antibodies
are associated with type 1 responses. IgE is primarily associated with mast cells,
and is involved in atopic reactions and mast cell signaling. Thus, the antibodies
produced during the humoral response use a wide variety of methods to eradicate
invading organisms.
Cell-Mediated Immunity
Intracellular pathogens like Leishmania hide inside host cells, and evade hu-
moral immunity. They can only be eradicated through macrophage activation, or
direct cytotoxic effects provided by cell-mediated immunity. There are two major
T cell effectors involved in cell-mediated immunity, CD4+ Th1 cells, and CD8+
CTLs. Th1 cells secrete IFN-γ, which activates the microbicidal properties of
macrophages. CTLs induce direct killing of infected cells through interactions with
MHC class I and also provide a source of IFN-γ.
Naı̈ve CD4+ T cells must encounter antigen in the context of an MHC class II
molecule only present on dendritic cells, macrophages, or B cells. When a T cell
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receives antigen plus co-stimulation, it is activated to become an effector T cell.
Exactly how T cells are instructed is not fully understood, but the cytokines found
in the microenvironment have been shown to play a major role in this process. IL-
12 is a cytokine that can be produced by macrophages or dendritic cells in response
to certain PRR, like TLRs. IL-12 can help to instruct T cells to differentiate into
Th1 cells, and thus is one of the driving cytokines of the Th1 response [45]. Th1
cells produce IFN-γ, which is important for macrophage activation. As mentioned
previously, macrophages require two signals to become activated in the classical
manner. One signal is IFN-γ, and the other can be provided in a variety of ways and
sensitizes the macrophage to respond to IFN-γ. Th1 effector cells can provide both
signals. IFN-γ is the primary cytokine produced by these cells, and CD40L interacts
with CD40 on the macrophage to deliver the second signal. Macrophage activation
transforms these cells into potent antimicrobial effector cells, inducing NO, IL-12,
TNF-α, MHC class II expression, CD40, and B7 expression. They become better
antigen presenters, and amplify the immune response through cytokine production
and antigen presentation [19].
Th1 cells are the coordinators of the cell-mediated immune response. In addi-
tion to inducing macrophage activation, they also recruit phagocytic cells to the site
of infection through the secretion of chemokines, such as CCL2. Th1 cells help
to activate the other effectors of the cell-mediated response, CD8+ T cells. These
cytotoxic cells recognize antigen in the context of MHC class I expressed on every
cell in the body. Their activation is tightly regulated, and they require more co-
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stimulation than CD4+ T cells to become activated. Naı̈ve CD8+ cells can receive
co-stimulation either through high levels of B7 expression on APCs like dendritic
cells, or through indirect T cell help primarily through the induction of high levels
of co-stimulatory molecules on the APC mediated by CD40-CD40L interactions
[66–68]. Once activated, CTLs target cells displaying the pathogen antigen in their
MHC class I on the cell surface. CTLs then release lytic granules containing per-
forin and granzymes, inducing apoptosis in the target cell. This response is espe-
cially important in the case of an infection, such as a virus, within the cytoplasm of
non-antigen presenting cells that do not bear MHC class II, and thus do not respond
to CD4+ T cell activation [19].
CD40-CD40L
The murine CD40L cDNA predicts a polypeptide of 260 amino acids (aa), with
a 22aa cytoplasmic domain, a 24aa transmembrane domain, and a 214aa extracel-
lular domain [69]. It is a type II membrane protein that presents an extracellular
carboxy terminus. The human gene is organized into 5 exons [70]. The first exon
encodes the intracellular, transmembrane, and a small portion of the extracellular
domain, and the remaining exons encode for the rest of the extracellular domain.
The murine gene also contains 5 exons [69].
CD40L is expressed primarily on activated T cells, but mRNA has been detected
in CD8+ and γ:δ T cells, as well as NK cells. Initial studies suggested a molecular
mass of 39kDa, but full length CD40L has been shown to be 32-33 kDa. The amino
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acid backbone predicts a protein of 29kDa, which suggests post-translational modi-
fications. An N-linked glycosylation site has been identified in human, murine, and
cattle CD40L. Human and mouse CD40L share 75% identity over their extracel-
lular domains. CD40L can be expressed as a soluble molecule in addition to the
cell surface form [71, 72]. Two shorter versions of 31 and 18kDa have been iden-
tified. These shorter soluble forms retain their ability to form trimers, bind CD40,
and induce biological signals. This indicates that CD40L may also act in part as a
cytokine [69].
CD40L interacts with cell-surface CD40 expressed on macrophages, DCs, and
B cells, as well as other cells. Cross-linking of CD40 with CD40L leads to many
signaling events. CD40 itself has no kinase domain, but several second messenger
systems are activated through CD40. There is evidence for recruitment of a variety
of TRAFs (TRAF-2, 3, 5, and 6), and Jak3 has also been shown to associate with
CD40 [73–76]. This signaling leads to a number of downstream events, including
NF-κB, NF-AT and AP1 activation [69, 74].
CD40 and CD40L belong to the tumor necrosis factor receptor family (TNF-
R) and the TNF family respectively. CD40 was first described on B cells, and
CD40L is primarily expressed on activated CD4+ T cells. The interaction be-
tween CD40-CD40L was first described in humoral immunity. This was shown
by the finding that patients suffering from hyper-IgM syndrome were character-
ized by mutations in their CD40L gene [69, 77, 78]. These patients displayed
impaired class-switching and a susceptibility to bacterial infections. The role of
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CD40L in humoral immunity was examined further in knockout mice deficient in
CD40L [79, 80]. These mice showed impaired class-switching to T cell dependent
antigens, similar to the effect of CD40L deficiency in humans. In addition, germi-
nal center formation was impaired in these mice. Treatment with an anti-CD40L
antibody also prevented germinal center formation and demonstrated a lack of B
cell memory from adoptive transfer [81]. Studies in CD40 deficient mice obtained
similar results [82], indicating that CD40-CD40L interactions are crucial for T cell
dependent antibody responses and B cell memory.
Many studies have also shown the importance of CD40-CD40L in cell-mediated
immunity [83–90]. CD40L is a potent inducer of IL-12 from macrophages and
DCs, indicating that CD40-CD40L interactions may be important in priming cell-
mediated immunity [83, 90, 91]. Incubation of T cell depleted splenocytes with a
Th1 clone resulted in IL-12p40 mRNA and protein that was abrogated with an anti-
CD40L antibody [83]. CD40L expressed on CHO cells was also shown to induce
IL-12p40 from DCs and macrophages [91]. The role of CD40L in cell-mediated
immunity is supported by the finding that hyper-IgM patients have been shown to
be more susceptible to opportunistic infections requiring a cell-mediated response
[92]. HIGM patients were impaired in their ability to respond to the intracellu-
lar pathogen Toxoplasma gondii through lack of specific T cell proliferation, IL-12
or IFN-γ [88]. CD40L was shown to induce IL-12 from macrophages and DCs
in response to T. gondii in healthy humans, leading to IFN-γ production and T cell
proliferation. Addition of soluble CD40L trimer was able to reverse the impairment
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in IFN-γ production from an HIGM individual and was able to reconstitute IL-12
induction in PBMCs from an infected patient. CD40L has also been shown to be
important in Th1-mediated autoimmune disease [87]. Blocking CD40L-CD40 in-
teractions through anti-CD40L antibody can prevent Th1-mediated TNBS-induced
colitis when administered during the induction phase of colitis. Administration
of anti-CD40L antibody prevented IL-12 induction, Th1 T cell priming, and sub-
sequent IFN-γ production responsible for inflammation associated with disease.
Treatment with anti-CD40L antibody following disease establishment was ineffec-
tive, demonstrating that CD40L may play an important role in the initiation of T
cell priming. A correlation between CD40-CD40L expression and disease state in
leprosy has also been observed [89]. CD40 and CD40L were readily detected in le-
sions of patients with tuberculoid leprosy, but not in those with lepromatous disease.
Tuberculoid leprosy is characterized by a Th1 response, while lepromatous leprosy
is characterized by a Th2 response. These data provide evidence for a significant
role of CD40-CD40L interaction in cell-mediated immunity.
CD40 ligation can induce differential outcomes, depending on the cell type ex-
pressing CD40. B cells are stimulated to proliferate, differentiate, and produce
Ig. As mentioned, CD40L stimulation is critical for germinal center formation and
class switching in response to T cell dependent antigens [79, 80]. CD40L stim-
ulation of B cells also leads to release of IL-6, IL-10, TNF-α, and expression of
adhesion molecules and co-stimulatory markers. In macrophages and DCs, CD40
activation results in enhanced survival, secretion of cytokines including IL-1, IL-6,
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IL-8, IL-10, IL-12, TNF-α, and NO synthesis [69, 93, 94]. CD40 ligation also in-
duces maturation of macropahges and dendritic cells, up-regulating expression of
ICAM-1, LFA-3, CD80, and CD86. Disruption of CD40-CD40L interactions leads
to reduced T cell proliferation and cytokine release [69, 93].
Leishmania
Overview and Life Cycle
Leishmania spp. were discovered by William Leishman and James Donovan
working independently in 1901-1903 [95]. Leishmania belong to the order Kineto-
plastida and the family Trypanosomatidae. Leishmania are single celled protozoa,
and are the etiological agents of the disease leishmaniasis. Leishmaniasis is en-
demic in nearly 100 countries worldwide, with almost all cases occurring in tropical
and sub-tropical areas. Humans are infected by 21 of the approximately 30 species
of Leishmania that infect mammals. Leishmania species are divided into Old World
and New World species by geographic location of endemic species [95]. The para-
site is carried by the female phlebotamine sandfly of the genus Phlebotamus in the
Old World or Lutzomyia in the New World.
Leishmania spp. have a two stage life cycle, consisting of the elongated, flag-
ellated promastigote, and the oval, non-motile amastigote (Figure 4). The pro-
mastigote is found in the mid-gut of the sandfly vector, where it matures into the
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Figure 4: Leishmania Life Cycle.
Adapted from CDC (http://www.dpd.cdc.gov/dpdx). Leishmania are intracellu-
lar parasites with 2 life stages, the promastigote, which resides in the gut of the
sandfly, and the amastigote, an obligate intracellular usually found in host tissue
macrophages. 1) A sandfly takes a blood meal injecting promastigotes. 2-4) Pro-
mastigotes are taken up by host tissue macrophages, where they transform into
amastigotes, replicate, and rupture the cell to infect others. 5-6) The sandfly takes a
blood meal from an infected individual, ingesting macrophages containing amastig-
otes. 7-8) Amastigotes transform back into promastigotes in the midgut of the sand-
fly and replicate.
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infective metacyclic form. When the sandfly takes a blood meal, promastigotes are
injected into the skin of the host. Promastigotes are rapidly taken up by host tis-
sue macrophages where they transform into amastigotes within the phagolysosome.
Amastigotes replicate within phagolysosomes and eventually rupture host cells, al-
lowing them to infect neighboring cells. The cycle is completed when a sandfly
takes a blood meal from an infected individual, ingesting macrophages containing
amastigotes. These amastigotes transform back into promastigotes in the gut of the
sandfly, and prepare to infect another host [95, 96].
Disease Manifestations
Leishmania spp. can cause three major clinical disease manifestations: cuta-
neous, mucocutaneous, and visceral leishmaniasis. The type of disease contracted
depends primarily upon the species of Leishmania involved. Cutaneous leishma-
niasis generally presents as a localized skin lesion (LCL) around the area of the
bite that self-heals over the course of weeks to months. Occasionally, diffuse cu-
taneous leishmaniasis (DCL) can develop, where multiple non-healing skin lesions
appear as parasites disseminate from the original site of infection. Leishmania ma-
jor, Leishmania tropica, and Leishmania amazonensis are some species that primar-
ily cause the cutaneous form of the disease [96]. Mucocutaneous leishmaniasis is
caused by dissemination of parasites to the mucous membranes, resulting in large
lesions in the nose, mouth, and throat, and cause severe disfigurement and scar-
ring. Mucocutaneous leishmaniasis can be caused by L. braziliensis. The most
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perilous form of the disease is visceral leishmaniasis, with parasite dissemination
to the visceral organs. Symptoms of visceral leishmaniasis include splenomegaly,
hepatomegaly, fever, diarrhea, and weight loss, and this disease is often fatal if not
treated. The Kala-azar, or black fever, refers to visceral leishmaniasis [95]. Species
known to cause viscerial leishmaniasis include L. chagasi, L. donovani, and L. in-
fantum [96].
Diagnosis and Treatment
Infection with Leishmania spp. is diagnosed most accurately by biopsy of the
lesion and visual detection of the parasite by microscopic observation or culture
of parasites from the lesion. Other methods of diagnosis include PCR, ELISA,
serology, and DTH responses. These methods are improving, but visual detection
of the parasite is still the best way to diagnose this disease [95, 96].
Treatments are costly and difficult to administer. The most common treatments
are intravenous injections of pentavalent antimonials like sodium stibogluconate
[95]. Treatment periods typically last three to four weeks, and side effects are
common. Other treatments include amphotericin B. A new oral drug, Miltefosine
has shown promise in treating some forms of the disease [97, 98].
No safe, effective vaccines exist for this disease. The only way to vaccinate
against leishmaniasis is to inoculate live organisms into the host. Historically, it was
shown that once an individual had contracted leishmaniasis, they were resistant to
re-infection. Children were exposed to the bite of a sandfly or were inoculated with
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material from a lesion in the buttocks to induce immunity and prevent disfiguring
lesions on the face. Later, inoculation of adults with live, virulent organisms was
used to induce protective immunity. This process is called leishmanization. In the
1980s a large-scale vaccination program was instituted in approximately 1.3 million
soldiers and civilians during the Iran-Iraq war [99]. Leishmanization led to lesions
approximately 5-10mm in diameter that self-healed in 4-6 months. However, 2-3%
of vaccinated individuals developed large, non-healing lesions that required treat-
ment. Vaccination with live parasites induces powerful immunity, as shown by
a recent study of volunteers in Iran [100]. Twenty-three human volunteers were
inoculated with 5x105 live L. major. 19 volunteers were “takes,” developing mea-
surable lesions that healed (two required treatment) within 6-13 months. Following
lesion resolution, 11 participants volunteered to be challenged with L. major to test
their immunity level. In participants who were “takes,” 100% protection from re-
infection was observed. Conversely, the administration of killed parasites with BCG
as an adjuvant had no effect on the incidence of natural infection [101]. However,
the incidence of lesions requiring treatment and the potential for secondary infec-
tion and other side effects from leishmanization has been deemed unacceptable in
most of the world. Thus, traditional leishmanization has been largely discontinued
due to safety concerns [99]. Vaccine development is a priority to reduce infection
levels and improve quality of life for at-risk individuals in endemic countries.
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Leishmania Genetics
Leishmania spp. are eukaryotes with unusual genetic characteristics. The genome
contains approximately 35.5Mb of DNA, and this is organized into 34-36 chro-
mosomes. The absolute number of chromosomes can change with species [102].
Leishmania chromosomes are generally diploid, but these parasites have a tendency
to become aneuploid or haploid for some chromosomes. The diploid state of the
parasite would seem to suggest a form of sexual reproduction, however, the parasite
replicates by asexual binary fission [102]. Leishmania spp. can also maintain small
linear or circular chromosomes, called mini-chromosomes. It is thought that these
arise from gene amplification under stress conditions, and may be stably maintained
or unstable, depending on the stress encountered. In addition to their nuclear chro-
mosomal DNA, Leishmania contain a kinetoplast, which is a mitochondrial-like
structure with many circular pieces of DNA [103]. The circular DNA is divided
into the maxi-circles and the mini-circles. Maxi-circles are analogous to the mi-
tochondrial DNA of higher eukaryotes. Mini-circles are thought to serve a role in
RNA editing as guide RNAs for addition or deletion of uracils.
Gene arrangement in Leishmania also has some differences from higher eu-
karyotes. Introns and cis-splicing, two characteristics of higher eukaryotes have not
been demonstrated in Leishmania [102]. The ribosomal RNA genes are organized
similar to those of higher eukaryotes, with multiple head to tail repeats with cod-
ing regions separated by non-transcribed spacers. Non ribosomal genes are found
as either single copy, paired loci, or tandem repeats. Highly expressed proteins
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are present in multiple copies in the genome, and are usually organized as tandem
repeats.
Trypanosomatids have clear homologs of the three major RNA polymerases.
Polymerase I promoters have been identified in rRNA loci and upstream of surface
proteins in T. brucei. Few RNA polymerase II promoters exist in these organisms as
of yet, although RNA polymerase II transcription has been demonstrated in multiple
leishmanial genes by susceptibility to α-amanitin [102]. It is not understood how
transcription of genes by RNA polymerase II is initiated in these organisms. Small
RNA genes and tRNA genes are transcribed by RNA polymerase III, as determined
by polymerase inhibitors α-amanitin and tagetitoxin [104, 105].
Leishmania also have an unusual way of processing mRNA. In higher eukary-
otes, genes are transcribed individually, then processed to remove introns and add
the 5’ cap and poly-A tail. Leishmania generate polycistronic RNA, similar to
prokaryotes. However, they have a unique method of processing RNA post-transcription.
In eukaryotes, a 5’ cap is added during transcription. An RNA triphophatase clips
the phosphate off the end of the growing RNA, leaving a diphosphate. A guanylyl
transferase attaches GMP from GTP to the 5’ end. Finally, two methyl transferases
methylate the capping guanosine and the penultimate nucleotide [106]. Leishma-
nia have a trans-splicing event following transcription that attaches a 39bp spliced-
leader sequence (also called the mini-exon) to the 5’ intergenic region at a splice ac-
ceptor site. Trans-splicing is followed by polyadenylation at the 3’ end. These two
events are spatially and temporally coupled, with polyadenylation occurring a fixed
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distance upstream of the mini-exon splice site [107, 108]. The trans-splicing reac-
tion of the downstream gene precedes the polyadenylation of the upstream gene.
Higher eukaryotes typically regulate gene expression through transcriptional
regulation. In Leishmania, however, most gene regulation occurs post-transcriptionally,
either through RNA stability, or protein stability. It is proposed that similar to other
organisms, regions of the 3’UTR may target mRNAs for deadenylation and sub-
sequent decapping and degradation. Several studies have identified regions of the
3’UTR that are responsible for mRNA stability, but the exact machinery and mech-
anism of this regulation is as yet unknown [109].
Immune evasion
For a pathogen to be successful, it must evolve ways to evade destruction by the
immune system. As mentioned, innate immunity is the first line of defense against
microbes, and by definition a pathogen must be able to circumvent innate immunity.
Leishmania have evolved several mechasisms of immune evasion. Immediately
upon being introduced into the host, Leishmania must battle complement present in
the blood. This organism has developed a mechanism that not only prevents com-
plement lysis, but subverts this host defense mechanism to improve targeting to the
host cell of choice, the macrophage. Leishmania metacyclic promastigotes are re-
sistant to complement lysis. Two surface molecules, lipophosphoglycan (LPG), and
gp63 are thought to be responsible for this resistance [110–112]. Both are efficient
binders of the C3 molecule of complement. The LPG on metacyclic promastigotes
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is nearly twice as long as that on log phase promastigotes, and prevents insertion
of the membrane attack complex (MAC) into the parasite membrane [112]. The
metalloprotease gp63 has been shown to transform cells into efficient activators of
complement [110]. Proteolytic activity was not required for complement activation,
but was required to prevent subsequent complement lysis, indicating that gp63 may
play a role in converting active C3b to the inactive iC3b. This has the added effect
of targeting these organisms to the CR3 receptor on macrophages, allowing for their
efficient phagocytosis [110, 111].
One of the most important adaptations to evade the immune response is the
development of an intracellular lifestyle. This allows the parasite to hide from de-
tection within host cells. The parasite lacks the ability to directly invade cells, and
relies on receptor mediated phagocytosis to infect macrophages. As mentioned,
they are efficiently opsonized by complement, and utilize the complement recep-
tors CR1 and CR3 for phagocytosis. CR3 is the primary complement receptor for
parasite uptake, as C3b is rapidly converted to iC3b by gp63 [110, 111]. In addition,
parasites can be ingested through mannose-fucose receptors, scavenger receptors,
and Fc receptors. Once inside the macrophage, they face a new set of challenges. As
described previously, the main function of the macrophage is to ingest and destroy
pathogens. Leishmania have evolved to subvert this cell and thrive in the highly
acidic phagolysosome. It has been shown the promastigote LPG may delay phago-
lysosome fusion through steric hindrance of membrane fusion, allowing time for
the organism to transform into the amastigote stage [111, 113]. This stage is highly
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resistant to the acidic environment found in the phagolysosome, and amastigotes
have been found to be more metabolically active at lower pH.
Usually, ingestion of an organism by the macrophage leads to activation of
the cell through PRRs, destruction of the organism, and presentation of antigen
to activate adaptive immunity. Leishmania enter macrophages quiescently, with-
out activating NO and ROI [111]. They fail to activate NF-κB, and fail to induce
up-regulation of co-stimulatory molecules. Some studies have shown that Leish-
mania are able to modulate MHC class II expression or antigen loading to interfere
with antigen presentation. In addition, they actively inhibit IL-12 production, and
render infected macrophages refractory to stimulation with IFN-γ [111, 114]. The
mechanisms involved in this subversion of events in the macrophage are still un-
clear, but many scenarios have been proposed. It has been shown that cross-linking
of Fc, complement, or scavenger receptors specifically inhibits IL-12 production
through calcium influx, and Leishmania are known to enter macrophages through
these paths [115]. Ligation of CR3 is also advantageous, because it does not acti-
vate NO and ROI. It has also been suggested that Leishmania inhibit PKC signaling,
thus inhibiting ROI [114]. In addition to inhibition of activating cytokines, infection
leads to the up-regulation of detrimental anti-inflammatory cytokines, like IL-10. It
is well known that Leishmania amastigotes are coated in host antibody, and studies
have shown that ligation of FcγR leads to a down-regulation of IL-12 and a subse-
quent up-regulation of IL-10 [25, 27]. Finally, Leishmania have developed ways to
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inhibit apoptosis signaling pathways, prolonging the life of the host cell and their
own survival [116].
In summary, Leishmania have adapted many ways of evading innate immunity,
from entering host cells to actively inhibiting host cell activation. Knowledge of the
mechanisms of immune evasion can suggest targets for drug and vaccine develop-
ment.
Murine Models of Leishmaniasis
The spectrum of human disease is also largely observed in murine systems, al-
lowing the mouse to be a reasonable in vivo model. The availability of various
strains of inbred mice and knockout animals has provided extensive characteriza-
tion of the immune response to Leishmania spp. Susceptible and resistant strains
have contributed to our knowledge of how this disease progresses and the important
immune cells and cytokines involved in disease resolution. Early on, it was noted
that many strains of mice were resistant to leishmanial infection, developing small
healing lesions. Some strains, however, were observed to be susceptible to disease,
eventually succumbing to large necrotic lesions [117]. The differences in disease
outcomes were determined to be related to differences in the T cell subsets activated
and the cytokines induced during infection [118, 119]. Resistant strains develop a
Th1 immune response to leishmanial infection, characterized by IFN-γ production.
Conversely, susceptible strains were found to develop a Th2 response to infection,
characterized by IL-4 and antibody production [43, 119]. This led to the murine
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model of L. major being used for many studies of the molecules pertaining to Th1
or Th2 responses.
Studies with resistant mice identified IFN-γ as the dominant cytokine in a heal-
ing response. Normally resistant mice deficient in IFN-γ [120] or the IFN-γ receptor
[121, 122] were shown to be more susceptible to leishmanial infection and treating
with anti-IFN-γ antibody also increased susceptibility to disease [123]. IL-12 has
been shown to be a major driving cytokine of the Th1 response, and this has been
demonstrated in Leishmania infection. Mice on a resistant background deficient in
IL-12 [124] or the IL-12Rβ2 [125] were found to be more susceptible to Leishma-
nia infection. In addition, treatment with recombinant IL-12 was shown to improve
disease outcome in susceptible BALB/c animals [126].
Studies of the susceptible BALB/c mouse showed that these mice developed a
Th2 response to Leishmania that resulted in the production of high levels of IL-4
[43, 118, 119]. IL-4 was shown to be largely responsible for the detrimental effects
of this response, because removing IL-4 increased resistance. IL-4 gene knockout
BALB/c mice were more resistant to infection with the MHOM/IL/81/FEBN1 sub-
strain of L. major [121]. Somewhat surprisingly, in these mice IFN-γ mRNA in
draining lymph nodes was found to be unchanged from that of wild-type animals,
as was mRNA expression of several other cytokine genes tested, indicating that
in these animals, removal of IL-4 is sufficient to improve disease outcome [121].
Other studies showed that treating mice before or early in infection with anti-IL-4
antibodies improved disease outcome [118, 127]. This effect was shown to be in-
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dependent of IFN-γ, because although treatment led to a slight increase in IFN-γ
mRNA in draining lymph nodes, addition of an anti-IFN-γ antibody had no effect
on anti-IL-4 mediated reduction in disease [127]. The addition of neutralizing anti-
IL-4 antibodies was also shown to enhance vaccine efficacy in BALB/c mice [128].
Studies of mRNA levels of IL-4 in draining lymph nodes from resistant and suscep-
tible strains of mice have shown that IL-4 expression correlates with disease sever-
ity, with more susceptible strains expressing higher levels of this cytokine [129].
IFN-γ levels were less informative, as the range of mRNA expression was smaller,
and had overlap among resistant and susceptible strains. These studies would seem
to indicate that in resistant mice, IFN-γ is important for resistance, but in suscepti-
ble BALB/c mice, resistance is dependent on interference with, or suppression of,
the induction of the initial Th2 response.
It has been shown that IL-4 is not the only cytokine responsible for susceptibility
in leishmaniasis. Noben-Trauth reported in 1996 that mice deficient in IL-4 were
not more resistant to the LV39 substrain of Leishmania major [130]. This work
called into question the role of IL-4 in susceptibility to Leishmaniasis. It was later
reported that the role of IL-4 in susceptibility differed according to the substrain of
Leishmania major used for infections [131]. IL-4 deficient mice infected with the
LV39 substrain were similarly susceptible when compared to wild-type controls.
However, IL-4 deficient mice infected with the IR173 substrain were more resistant
than wild-type mice. A role for IL-13 was shown in enhanced resistance to infec-
tion seen in IL-4Rα knockouts when compared to IL-4 gene knockouts or wild-
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type controls [131]. This study also found a lack of increased IFN-γ production
even in the presence of a more resistant phenotype and the lack of Th2 cytokines.
They later proposed that the differences in susceptibility seen among the different
strains were due to the intrinsic differences in susceptibility to killing by IFN-γ ac-
tivated macrophages [132]. The IR173 and Friedlin V1 substrains were found to be
more susceptible to macrophage killing induced by IFN-γ than the LV39 strain, and
Noben-Trauth et al. proposed that in this case, resistance is achieved by the absence
of deactivating signals without the requirement for IFN-γ upregulation.
IL-10 has also been shown to play an important role in disease progression.
Mice deficient in IL-10 were more resistant to leishmanial infection, and treating
mice with anti-IL-10R also improved disease outcome [27, 133]. Noben-Trauth et
al. showed in 2003 that IL-10 might be the additional factor controlling disease sus-
ceptibility [132]. They found that when IL-10 was removed in addition to IL-4Rα,
BALB/c mice became resistant to the substrain LV39 that they were still susceptible
to with IL-4Rα or IL-10 deficiency alone.
The powerful mouse model has also been used to examine potential vaccine
candidates. As previously mentioned, there is no safe vaccine for leishmaniais, and
with increasing drug resistance there is a focus on development of an improved vac-
cine candidate. Due to the safety concerns of leishmanization, many vaccination
approaches have been examined. Studies with killed parasites, subunit vaccines,
and DNA vaccines have had varying degrees of success [134]. Some suggest that
parasite antigen persistence is required for continued immunity to Leishmania in-
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fection, because when sterile cure is achieved mice lose immunity to re-infection
[135, 136]. This may account for the lack of long term protection with killed or
subunit vaccines and the improved ability of DNA vaccines to provide protection
[134]. Thus many labs have devoted efforts to developing attenuated organisms for
use as vaccine candidates. Attenuation with γ-radiation led to protection of resistant
CBA mice [137]. In addition, attenuation of L. major and L. mexicana under gen-
tamycin pressure induced significant protection against challenge with wild-type
organisms [138]. However, these methods are impractical for the clinic because of
the potential for revertants. Genetically defined knockout parasites have also been
developed to generate attenuated vaccine candidates, and have less potential for re-
version to virulent forms because of irreversible genome changes [134]. L. major
dhfr-ts- parasites are double knockout auxotrophs that require thymidine for sur-
vival in macrophages. These parasites were incapable of causing disease in BALB/c
mice, but persisted for up to 2 months [139]. When challenged with wild-type or-
ganisms, BALB/c mice that had been vaccinated were significantly protected. In
addition, this strain was shown to provide partial protection against L. amazonensis
in both BALB/c and C57BL/6 mice, with mice developing lesions 40-75% smaller
in BALB/c mice, and 57% smaller in C57BL/6 mice [139]. L. mexicana lacking
cysteine proteinase genes are attenuated in BALB/c mice and were able to provide
some protection against challenge [140]. L. major lacking lpg2 (Golgi guanosine
diphosphate-mannose transporter) failed to induce lesions, but persisted at low lev-
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els [141]. These parasites were shown to induce protection in BALB/c animals
[142], but protection in C57BL/6 mice required CpG DNA as an adjuvant [143].
One potential problem of attenuation is loss of immunogenicity to generate a
protective response. Streit et al. showed in L. chagasi that attenuated versions of
the parasite with dhfr-ts knockouts were unable to provide protection against chal-
lenge, while infection with virulent parasites provided protective immunity [144].
In addition, the protective immunity observed in mice with dhfr-ts mutants was
not transferable to the rhesus monkey model. While the attenuated strain persisted
without pathogenicity, it was unable to provide protection against challenge [145].
Thus it is likely that adjuvants of some variety will be required for attenuated para-
site vaccines to transfer to the clinic.
CD40L and Leishmaniais
The co-stimulatory molecule CD40L is well characterized, and has been demon-
strated in multiple studies to play important roles in disease progression in leishma-
niais. Mice lacking CD40 or CD40L have been shown to be more susceptible to
Leishmania infection [84, 146–149]. Treatment with exogenous soluble CD40L
could restore resistance in CD40L-/- C57BL/6 mice [147]. Furthermore, adminis-
tration of anti-CD40 antibodies was shown to induce IL-12 and protect mice from
Leishmania challenge [150]. Anti-CD40 antibodies were also shown to induce
macrophage killing of parasites and act synergistically with antimony therapy to
improve disease outcome [148, 149].
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Previously, we have shown that the addition of CD40L to leishmanial antigens
improved disease outcome and provided protection against challenge with virulent
organisms [151]. In addition, CD40L trimer DNA has been successfully used to
vaccinate mice against Leishmania infection [152]. Thus, we hypothesized that
transgenic organisms expressing murine CD40L would be less virulent and more
immunogenic than wild-type organisms, and would be an improved vaccine alter-
native to traditional leishmanization.
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CHAPTER 2: MATERIALS AND METHODS
Mice
Six to eight week old BALB/c or C57BL/6 female mice were purchased from
Charles River Laboratories (Wilmington, MA) and Taconic Inc. (Rockville, MD)
respectively. SCID mice on a BALB/c background, CD40-/-, and CD40L-/- mice
on a C57BL/6 background were obtained from Jackson Labs (Bar Harbor, ME).
All mice were maintained in HEPA-filtered caging units (Thoren Caging Systems,
Hazelton, PA) at the University of Maryland (College Park, MD). Mice were used
for experiments at 6-10 weeks of age. All protocols were approved by the Uni-
versity of Maryland Institutional Animal Care and Use Committee (IACUC). See
Table 1 for a list of mouse strains used in this study.
Parasite culture
Promastigotes of the Leishmania major Friedlin strain, clone V1 (MHOM/IL/
80/Friedlin) were used throughout. Parasites were maintained in BALB/c mice and
cultured in vitro. Promastigotes were cultured in 50:50 media, which is composed
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Table 1: Mouse strains used in study.
Expected
phenotype
Phenotype of L. major
Strain Rationale of L. major CD40LE
BALB/c Susceptible mouse model Progressive
Lesions
Attenuated













Deficient in CD40L. Used to
determine if parasite derived
CD40L responsible for attenu-







Lack CD40, the receptor for
CD40L. Used to confirm CD40L
responsible for attenuated pheno-






of 50% M199 media (CellGro) and 50% Schneider’s Drosophila Medium (Sigma
Aldrich, St. Louis, MO) supplemented with 10% heat inactivated fetal bovine serum
(HI-FBS), 100U of penicillin G per mL, 100µg of streptomycin per mL, and 2mM
glutamine. 100µg/mL of nourseothricin (Werner BioAgents, Germany) was added
to cultures of transgenic parasites to select for resistant parasites.
Infections, Immunizations, and Parasite Quantitation
For mouse infections, parasites were washed in Hanks balanced salt solution
(HBSS) (CellGro, Lawrence, Kansas), centrifuged at 1000 x g for 10 minutes, and
resuspended in HBSS for subcutaneous injection into the footpad in a volume of
approximately 20µL. For standard BALB/c infections 1x105 organisms were in-
jected into the right hind footpad. 5x105 parasites were used for the more resis-
tant C57BL/6 mice. For immunizations with live parasites, mice were infected
with 5x104 wild-type, empty vector, or CD40LE L. major in the right hind foot-
pad. Three to five weeks later they were challenged with wild-type L. major in the
contralateral footpad (1x105 for BALB/c, 5x105 for C57Bl/6). When mice were
infected in the ear dermis, 1x104 parasites were injected in a 10µL volume. Dis-
ease progression was monitored twice weekly using a digital caliper to measure
footpad thickness. The lesion size for standard infections was calculated as the
difference between the thickness of the infected and uninfected footpad as previ-
ously described [27]. For immunizations where both footpads were infected, lesion
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size was reported as the thickness of the infected footpad only. Ear lesions were
measured as the diameter of the lesion. Parasite burdens were determined by serial
dilution of single cell suspensions made from excised footpads, lymph nodes, or
spleens as previously described [153]. Briefly, organs were harvested into HBSS
and were then forced through a cell strainer. Cells were washed through the strainer
with 10mLs of HBSS and centrifuged at 500 x g to remove cell debris. Supernatants
were transferred to a new tube and centrifuged at 1000 x g to harvest amastigotes.
Cell pellets were resuspended in 1mL of HBSS. For footpad burdens, samples were
diluted 1000 fold with HBSS before dilution plating in a 1:5 serial dilution scheme.
Parasite burden was determined as the final well containing live parasites after 5-
7 days incubation at 25°C. For in vitro infections of macrophages, parasites were
washed and counted as for mouse infections and added to wells in a small volume
of HBSS (20-50µL).
Gene splicing by overlapping extension (SOE) PCR
The 126bp gp63 signal sequence from L. amazonensis was amplified from the
plasmid U11 using the forward primer 5’TAACCCGGGATGTCCGTCGACAGCAG3’
(F1) and the reverse primer 5’AAATTGCCTTCTCATGGCGTGTGCCCACGC3’
(R1) from IDT DNA Technologies, Inc. (Coralville, IA). The CD40L extracel-
lular domain (aa#87-260) was amplified from the plasmid pORF-mCD40L from
Invivogen (San Diego, CA) using the forward primer 5’TGGGCACACGCCAT-
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GAGAAGGCAATTT3’ (F2) and the reverse primer 5’TTAGCTAGCGAAGACT-
GCCAGCATCAGC3’ (R2) also from IDT. The hybrid gp63CD40LE product was
amplified using splice overlap extension PCR as previously described [154]. The
gp63CD40LE product was then ligated into the TA cloning vector pCRII (Invitro-
gen, San Diego, CA) and grown in DH10B competent E. coli (Invitrogen). Colonies
were grown on LB plates containing ampicillin and X-Gal, 10 white colonies were
chosen, and plasmids were extracted using the mini-prep kit (Qiagen). Purified
plasmid was digested with XmaI and NheI (New England BioLabs [NEB], Bev-
erly, MA) to detect clones containing the insert. Clones positive for the insert by
enzymatic digest were then sent for sequencing (Core Sequencing Facility, Uni-
versity of Maryland, College Park, MD). One clone with the correct sequence was
excised from the TA vector using the restriction enzymes XmaI and NheI and lig-
ated into the Leishmania vector pIR1SAT (pSAT) (a kind gift from Stephen Bever-
ley, Washington University, St. Louis, MO) that had been digested with XmaI and
XbaI (NEB). This plasmid contains 5’ and 3’ portions of the 18srRNA gene of L.
major to allow for insertion into the genome, as well as intergenic regions neces-
sary for mini-exon splicing and polyadenylation. This allowed for stable transgenic
constructs to be generated through homologous recombination. The plasmid also
contains a streptothricin acetyl transferase (SAT) gene for selection with antibi-
otics from the streptothricin family, such as nourseothricin. Insertion into the pSAT
vector was confirmed using XmaI and BglIII (NEB) (another downstream site in
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pSAT). pSAT CD40LE was linearized using the restriction enzyme SwaI (NEB)
and gel purified using a kit from Qiagen.
Electroporation
Leishmania major were transformed with 10µg of linearized plasmid using elec-
troporation as previously described [154]. Briefly, 1x108 parasites were resus-
pended in 400µL of electroporation buffer (21mM HEPES, 137mM NaCl, 5mM
KCl, 0.7mM Na2PO4) and mixed with plasmid. Following electroporation, cells
were plated on blood agar plates containing 100µg/mL of nourseothricin. Sin-
gle colonies were selected and grown in 50:50 broth culture containing 100µg/mL
nourseothricin. Clones were labeled no. 13 for the clone of pSAT-CD40LE used for
the transfection and sequentially numbered from colonies chosen at random from
blood agar plates, resulting in the nomenclature L. major CD40LE 13.2 (no. 13 for
pSAT clone,no. 2 for colony from blood agar plate).
RT-PCR
RNA was isolated using the Trizol method according to the manufacturer’s pro-
tocol (Invitrogen) as previously described [154]. RNA was then converted to cDNA
using random hexamer primers (Invitrogen). Then gp63 was amplified using the
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forward primer 5’ATCCTCACCGACGAGAAGCGCGAC3’ (F3) and the reverse
primer 5’ACGGAGGCGACGTACAACACGAAG3’ (R3) from IDT. CD40L was
amplified using the same primers used to generate the original PCR product (F2,
R2).
Western Blot
1x108 parasites were harvested from late log/stationary phase cultures, washed
once with HBSS and resuspended in 1mL of ice-cold lysis buffer as previously
described [155]. Lysates were cleared by centrifugation (13,000 rpm, 10 min,
4°C). Equal amounts were then loaded on 18% SDS-polyacrylamide pre-cast gels
(BioRad). After separation, proteins were transferred onto a polyvinylidene di-
fluoride membrane for 1h at 100V. Membranes were then blocked in 5% nonfat
milk in TBS-T for 1h at room temperature, washed briefly and incubated with
the primary antibody (1:200) (polyclonal goat anti-murine CD40L, R&D Systems
cat#AF1163) overnight at 4°C. Membranes were washed in TBS-T and incubated
with secondary antibody (anti-goat HRP diluted 1:5000) for 1h at room temper-
ature. Membranes were then developed using ECL chemiluminescent substrate
(Amersham Biosciences) according to the manufacturer’s instructions. For non-
denaturing gels, samples were resuspended in sample buffer without reductance
and immediately loaded onto gels without SDS for native PAGE.
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ELISA
ELISAs were done using standard protocols as previously described [35] with
the following antibody pair from R&D Systems: anti-CD40L (cat#AF1163) and bi-
otinylated anti-CD40L (cat#BAF1163). Cytokine production was determined using
the following antibody pairs from BD Pharmigen (San Jose, CA): IL-12p40, C15.6
and C17.8; TNFα, G281-2626 and MP6-XT3.
MTT assay
MTT assays were performed as previously described [154]. 1x106 L. major, L.
major pSAT or L. major CD40LE 13.2 were inoculated into 5mL of 50:50 media.
100µL of culture was harvested at each time point and loaded onto a 96 well plate.
20µL of MTT (stock 5mg/mL) (Sigma, St. Louis, MO) was added to wells for 2h
at room temperature, followed by 100µL of DMSO to lyse cells for 30min at room
temperature in the dark. Plate was read on an ELISA plate reader at 550nm.
Macrophages
Bone marrow derived macrophages (BMMφ) were generated as previously de-
scribed [155]. Briefly, bone marrow was flushed from BALB/c femurs and tibias
and the cells were plated in Dulbecco’s Modification Eagle’s Medium supplemented
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with F12 (DMEM-F12) (DIFCO) supplemented with 10% heat inactivated fetal
bovine serum (HI-FBS) (Hyclone, Logan, UT), 100U/mL of penicillin (Fisher Sci-
entific), 100µg/mL of streptomycin (Fisher Scientific), 2mM glutamine (Fisher Sci-
entific), and 20% L-cell conditioned medium (LCCM). Cells were fed with 10mL
of this media on day 2, and adherent cells were used on day 7-14.
L929 Cells
Control L929 cells and L929 cells stably transfected with CD40L were provided
by Brian Kelsall (National Institutes of Health). Cells were cultured in RPMI su-
plemented with 10% HI-FBS, 100U/mL penicillin, 100µg/mL of streptomycin, and
2mM glutamine. 300µg/mL of genetecin was added to transfected cells to maintain
CD40L expression.
Macrophage Stimulation
For some experiments, macrophages were primed with 100U/mL of IFN-γ overnight.
Macrophages were washed three times with PBS prior to stimulation to remove
residual IFN-γ. LPS was used at a concentration of 10ng/mL. L929 and L929
CD40L cells were added at a 1:1 ratio to BMMφ. When soluble Leishmania antigen
was used, it was added at a concentration of 50µg/mL. For certain experiments, par-
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asites were opsonized prior to infection by incubation in 5% C5d serum in HBSS
for 15 minutes at 37°C. Parasites were washed with HBSS before macrophage in-
fection.
Immunofluorescent staining of amastigotes
Bone marrow derived macrophages from BALB/c mice were plated 1x105 cells
per coverslip and infected with a 20:1 ratio of L. major, L. major pSAT, or L. major
CD40LE for 2 hours. Monolayers were thoroughly washed and fixed with methanol
for 15 minutes at 4°C. Coverslips were blocked with 5% FBS in PBS for 15 minutes
and stained with polyclonal murine anti-L. major serum diluted 1:250 in blocking
buffer for one hour at room temperature. The cells were washed and a FITC con-
jugated goat anti-murine secondary antibody (1:100) was added for one hour. The
cells were counterstained with propidium iodide. Coverslips were mounted with
Mowiol and viewed using a fluorescent microscope (Zeiss).
Immunofluorescent staining of NF-κB
BMMφ were plated with 1x105 cells per coverslip and infected with a 20:1
ratio of L. major or L. major CD40LE for 45 minutes at 37°C. Cells were washed
with warm PBS and fixed in 4% paraformaldehyde for 15 minutes. Cells were
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then washed and incubated in blocking buffer (1% normal goat serum and 0.1%
saponin) for 15 minutes at room temperature. Cells were incubated with primary
mouse monoclonal anti-p65 (clone F6) for 1 hour. Cells were washed and stained
with FITC conjugated goat anti-mouse antibody diluted 1:100 in blocking buffer
for 1 hour. During the last 10-15 minutes of this incubation, the cytoplasm was
counterstained with 0.008% final concentratin of Evan’s Blue. Coverslips were
then mounted on slides with mowiol and viewed under a fluorescent microscope.
Nitric Oxide Production
BMMφ were plated with 2x105 cells per well in 24 well tissue culture dishes
and stimulated under various conditions. Supernatants were collected after 24 hours
of incubation at 37°C, and nitric oxide concentrations were determined using the
Griess assay. Standards were created by 1:10 serial dilution of 100µM NaNO2.
Standards and samples were loaded onto a 96 well plate and Griess Reagent was
added. Griess reagent consists of 2% phosphoric acid, 1g sulfanilamide, and 0.1g
naphthylethylene diamine hydrochloride with H2O to a final volume of 100mL.
Plates were read approximately 5 minutes later on an ELISA plate reader at 550nm.
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Flow Cytometry for CD40
BMMφ were plated with 2x106 cells per well in 6 well tissue culture dishes.
Cells were infected with a 20:1 ratio of parasites to macrophages overnight. Cells
were then harvested into flow tubes using Cell Stripper. Cells were fixed with 4%
paraformaldehyde for 15 minutes, washed, and were then stained for surface ex-
pression of CD40 with a PE conjugated anti-CD40 antibody for 45 minutes in the
dark at 4°C. Cells were then run on a FACSCalibur machine and analyzed using
CellQuest software.
DO11.10 T cell assay
BMMφ were plated 2x105 cells per well in a 48 well plate. Macrophages were
infected with wild-type or transgenic L. major and concurrently given ovalbumin
(150µg/mL). T cells were isolated from the spleens of DO11.10 mice using the
murine SpinSep T cell enrichment kit from Stem Cell Technologies. The proce-
dure was performed according to the manufacturer’s instructions. Briefly, spleens
were passed through cell strainers with PBS containing 2% FBS (recommended
medium). Cells were pelleted at 200 x g for 10 minutes and resuspended in 2mL
recommended medium. 20µL of antibody cocktail was added, and cells were mixed
and incubated for 15 minutes at 4°C. Cells were washed and resuspended in 2mL
of recommended medium. 500µL of dense particles were added for 20 minutes on
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ice. Then cell suspensions were diluted with 6mL of recommended medium and
layered over density medium. T cells were at the interface of the density medium
after centrifugation at 1200 x g for 10 minutes with the brake off. Harvested cells
were washed with PBS before use. T cells were resuspended in 500µL of warm
PBS. Stock CFSE (5µM) was diluted 1:100 in PBS and added 1:1 to resuspended
cells. Cells were mixed and incubated for 7 minutes at room temperature in the
dark. Staining was stopped with the addition of an equal volume of FBS. Cells
were then centrifuged and counted for use in T cell proliferation assay. T cells
were added to macrophages approximately 3 hours post macrophage stimulation,
and cells were incubated for 96 hours before CFSE dye dilution was measured by
flow cytometry. Positive proliferation was determined by multiple peaks shifting
left due to dye dilution following cell division.
Real Time PCR
Real Time PCR was performed on draining lymph nodes from ear infections.
Lymph nodes were placed in Trizol immediately following removal. Tissue was
disrupted with small pestles (Quiagen) in 1.5mL microfuge tubes. RNA was quan-
tified by spectrophotometry, and cDNA was generated using the ThermoScript kit
from Invitrogen according to the manufacturer’s instructions. Real Time PCR was
performed for cytokines IL-10, IL-4, and IFN-γ using the following primer sets
from IDT DNA:
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IL-10 forward 5’AAGGACCAGCTGGACAACAT 3’;
IL-10 reverse 5’ TCTCACCCAGGGAATTCAAA 3’;
IL-4 forward 5’TCAACCCCCACGTAGTTGTC 3’;
IL-4 reverse 5’ACGTTTGGCACATCCATCTC 3’;
IFN-γ forward 5’ GCGTCATTGAATCACACCTC 3’;
IFN-γ reverse 5’ TGAGCTCATTGAATGCTTGG 3’.
HPRT was used as a housekeeping gene for normalization with the primers: for-
ward 5’AAGCTTGCTGGTGAAAAGGA 3’; reverse 5’ TTGCGCTCATCTTAG-
GCTTT 3’. Dissociation curves were performed for every run, and data was only
analyzed if the curve showed a single peak. Samples from all primer sets were also
run on a gel initially to ensure singe band products.
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CHAPTER 3: RESULTS
Plasmid construction and transformation of Leishmania major
Transgenic L. major parasites expressing the extracellular domain of CD40L
were developed using Splicing Overlap Extension (SOE) PCR [154, 156, 157].
This technique attached the gp63 signal sequence from L. major to the extracellular
domain of CD40L (CD40LE) (Figures 5 and 6). It has previously been shown
that the extracellular domain of CD40L can be expressed and secreted in a biolog-
ically active trimer by E. coli, and we used the same amino acids (#87-260) from
the 18kDa protein described in that study for our molecule [72]. The PCR prod-
ucts were generated as described in Materials and Methods. First, the gp63 signal
sequence from L. major was generated, as was the CD40L extracellular domain
(Figure 6A). These two products were joined in the SOE PCR reaction (Figure 6B).
The hybrid SOE PCR product was placed in the TA vector for stabilization. Clones
with identified inserts were then sent for sequencing. A clone with a perfect se-
quence (number 14) was digested and gel purified for ligation into the leishmanial
vector pIR1SAT (pSAT).
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Figure 5: SOE PCR Reactions.
The CD40LE construct was generated using SOE PCR. First, the gp63 signal se-
quence was amplified. Then the CD40L extracellular domain was separately am-
plified. These first reactions used primers that contained overhangs complementary
to the other sequence. The two products were then put into the SOE PCR reaction,
which allowed the generation of the hybrid gp63CD40LE product.
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Figure 6: SOE PCR Reactions. Gel Photos.
A) The signal sequence from gp63 was amplified in the first PCR reaction (PCR#1,
Lanes 7-9). Its size is 126bp. The 590bp extracellular domain from CD40L
(CD40LE) was amplified in the second PCR reaction (PCR#2, Lanes 3-4). B) The
SOE PCR reaction was done using a temperature gradient and generated a 716bp
hybrid containing the gp63 signal sequence and the CD40L. The product was gel
purified from Lane 6 (also marked with an asterisk) for ligation into the TA vector.
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This vector has several important features that allow for gene expression in
Leishmania (Figure 7). First, it contains the 5’ and 3’ ends of the 18srRNA (SSU)
gene of L. major to allow for stable integration of the plasmid into the genome. This
can be exposed by digestion of the plasmid with SwaI and gel purification of the
larger product, resulting in linear plasmid for transformation and insertion (Figure
8). The plasmid also contains intergenic regions required for mini-exon attachment
and polyadenylation for mRNA processing. Finally, it contains both an ampicillin
resistance gene for plasmid selection in bacterial cells, and a streptothricin acetyl
transferase (SAT) gene for resistance to the streptothricin family of antibiotics for
selection of parasites containing the plasmid. Following ligation into pIR1SAT,
DH10B cells were transformed, and ampicillin resistant colonies selected. Plasmid
was isolated from these colonies and assayed for CD40LE insertion by digestion
with XmaI and BglIII. Again, clones that were determined to have the insert by
digestion were sent for sequencing. Clone 13 was chosen for transformation of L.
major. The plasmid was then linearized with the restriction enzyme SwaI and gel
purified to remove the ampicillin resistance gene. Leishmania major were electro-
porated with the linearized plasmid and plated onto blood agar plates containing
nourseothricin. Colonies were chosen and sequentially numbered from the electro-
poration reaction resulting in the nomenclature of 13.2; 13 for the pSAT clone used,
and 2 for the colony chosen from electroporation.
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Figure 7: pIR1SAT Leishmania vector.
The vector contains the 5’ and 3’ ends of the L. major 18srRNA (SSU) gene for sta-
ble insertion into the Leishmania genome and intergenic regions (CYSIR) required
for mini-exon attachment and polyadenylation. It contains a multiple cloning site
(at the restriction enzymes SmaI/XmaI) where the CD40LE SOE PCR product was
inserted. The plasmid also contains a streptothricin acetyl transferase gene to pro-
vide resistance to this family of antibiotics.
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Figure 8: Insertion of pIR1SAT into the genome.
pIR1SAT CD40LE was linearized using the restriction enzyme SwaI. After lin-
earization and gel purification of the plasmid, Leishmania major were transformed
and the plasmid was able to integrate into the 18srRNA gene for stable expression.
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Transgenic parasites express CD40L
Antibiotic resistant clones were assayed for expression of CD40L using a vari-
ety of methods. First, we examined mRNA expression in promastigotes by RT-PCR.
CD40L mRNA was present in three clones of CD40LE L. major, designated 13.1,
13.2, and 13.4 (Figure 9A, lanes 2-4). No CD40L mRNA was detected in wild-type
organisms (Figure 9A, lane 1). A leishmanial surface protein, gp63, was used as a
loading control. It was detected in both wild-type and transgenic Leishmania major
promastigotes (Figure 9A lower panel). To confirm the mRNA data, a western blot
was performed on whole cell lysates (Figure 9B). L929 cells stably transfected with
full-length CD40L were used as a positive control (Figure 9B lane 1). Wild-type
L. major organisms were used as a negative control (Figure 9B lane 2). All three
clones were also shown to express CD40L protein by western blot (Figure 9B, Lane
3-5). CD40L from transgenic L. major CD40LE was smaller than CD40L detected
in L929 cells because L929 cells expressed full length CD40L. L. major CD40LE
lack the transmembrane domain, allowing for the secretion of the protein. Secretion
of CD40L was measured by ELISA (Figure 10). CD40L protein was detected in the
supernatants of cultures of transgenic parasites in a dose dependent manner (Figure
10), but not in the wild-type cultures (data not shown), indicating that CD40L was
secreted from the parasite.
After determining that promastigotes expressed CD40L, we examined expres-
sion by the amastigote form of the organism. BMMφ were infected at a 20:1 ratio of
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Figure 9: L. major CD40LE promastigotes express CD40L mRNA and protein.
A) Promastigote mRNA was isolated from wild-type L. major (Lane 1) and three
clones of L. major CD40LE (Lanes 2-4) and assayed for CD40L (upper panel)
and gp63 (lower panel) by RT-PCR. gp63 was used as a loading control. CD40L
was detected in transgenic parasites, but not in wild-type organisms. B) CD40L
protein was detected by western blotting of whole cell lysates from control L929
cells stably transfected with CD40L (Lane 1) and L. major CD40LE (Lanes 3-5).
CD40L was not detected in wild-type L. major (Lane 2).
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Figure 10: Secretion of CD40L by transgenic parasites.
Promastigotes were plated in 1:2 serial dilutions for 24hr. Secretion of CD40L into
the supernatant was measured by ELISA.
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parasites to macrophages with either wild-type or CD40LE organisms. Two hours
after infection, monolayers were washed thoroughly to remove unbound parasites
and visually checked to ensure the removal of promastigotes. At indicated times
following infection, RNA was harvested and assayed for CD40L. CD40L was de-
tected from monolayers infected with transgenic parasites, but not from uninfected
BMMφ or from BMMφ infected with wild-type L. major (Figure 11, top panel).
The presence of parasites was confirmed by the detection of gp63 mRNA (Figure
11 middle panel). HPRT was used as an indicator of equal loading of macrophage
cDNA (Figure 11, lower panel). L. major CD40LE promastigotes were used as
a positive control (Figure 11, far left lane). To examine protein expression by
amastigotes, BMMφ were infected with transgenic parasites and supernatants were
harvested at the indicated time points (Figure 12) to measure soluble CD40L levels.
CD40L was detected in supernatants of Mφ infected with transgenic parasites, con-
firming amastigote protein expression. Taken together, these data demonstrate that
the transgenic Leishmania organisms we generated are able to express and secrete
CD40L. Clone 13.2 was chosen for the remainder of the study.
Expression of CD40L by transgenic parasites is stable
To determine if the CD40L produced by the transgenic parasites was stably ex-
pressed, BALB/c mice were infected with L. major CD40LE 13.2. Six weeks later,
parasites were harvested and assayed for sCD40L production by ELISA (Figure
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Figure 11: Amastigote mRNA expression.
BMMφ were infected for 24, 48, or 72 hours with wild-type or CD40L organisms,
or left uninfected. At each time point, RNA was isolated and RT-PCR was per-
formed for CD40L (top panel), gp63 (middle panel), and HPRT (bottom panel).
Transgenic promastigotes were used as a positive control.
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Figure 12: CD40L release from macrophages.
Macrophages were plated 2x105 cells/well in a 48 well dish and infected with a
30:1 ratio of CD40L parasites. Two hours later, unbound parasites were washed
away and 300µL on media was added. At indicated timepoints, supernatants were
harvested and CD40L was detected by ELISA.
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13). Promastigotes in culture are shown as a positive control (hatched bars). Para-
sites isolated from the footpads of mice (filled bars) expressed comparable amounts
of sCD40L to parasites that had been maintained under antibiotic selection, indicat-
ing that the expression of CD40L by the transgenic parasite is stable. This would
suggest that the plasmid successfully integrated into the L. major genome.
sCD40L produced by transgenic Leishmania forms trimers
Previous studies have shown that sCD40L can form trimers and be biologically
active [72]. To examine the ability of our transgenic parasite to produce trimers, a
non-denaturing gel was run, and a western blot was performed. L929 cells stably
transfected with CD40L were used as a positive control. CD40L from L929 cells as
well as parasite derived CD40L formed trimers, which appeared at around 60kDa
on the non-denaturing gel (Figure 14A), compared to ≈20kDa on a standard SDS-
PAGE gel (Figure 14B). This indicates that the sCD40L produced by our parasites
is capable of forming trimers.
Transgenic parasites are as healthy as wild-type
We next determined whether the insertion in the 18srRNA gene had any effect
on the viability and growth of the parasite. To assay the growth rate of the organ-
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Figure 13: CD40L secretion from footpad derived parasites.
Parasites were isolated from the footpads of mice infected with L. major CD40LE
for six weeks (filled bars) and allowed to return to promastigotes without addition
of antibiotic selection. Promastigotes were then plated in two dilutions in 50:50
media for 24hr. Supernatants were harvested and assayed for CD40L by ELISA.
Promastigotes that had been cultured in antibiotic selection and were not footpad
derived were used as a positive control (hatched bars).
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Figure 14: Parasite derived CD40L forms trimers.
A) Whole cell lysates from L. major (Lane 1), L929 cells transfected with CD40L
(Lane 2), and L. major CD40LE (Lane 3) were run on a non-denaturing gel. No
CD40L is detected in wild-type parasites, while CD40L trimers are detected in
L929 and CD40LE cells at ≈50-60kDa. B) Whole cell lysates from L929 CD40L
cells (Lane 1), L. major (Lane 2), and L. major CD40LE (Lane 3) were run on an
SDS-PAGE gel. Monomer CD40L was detected ≈25 kDa in L929 and CD40LE
cells, but not in wild-type L. major.
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isms, an MTT assay was performed. This assay measures the metabolic rate of the
organism by the conversion of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) to formazan. All three organisms have the same growth curve, in-
dicating that the insertion has no effect on replication and metabolism rate of the
parasite (Figure 15). Next, we infected bone marrow derived macrophages with the
transgenic organism to ensure that the parasites were still able to invade host cells
and turn into amastigotes. Unstimulated BMMφ were plated on coverslips and in-
fected for two hours with either L. major (Figure 16A), L. major pSAT (Figure
16B), or L. major CD40LE 13.2 (Figure 16C). Cells were fixed with methanol and
stained with murine polyclonal anti- L. major serum. There was no difference be-
tween the numbers of wild-type or transgenic organisms at two hours post-infection
(Table 2), indicating that there is no defect in the ability of transgenic organisms to
invade host cells and transform into amastigotes.
To confirm the viability of the transgenic organisms, we infected SCID mice
on a BALB/c background with 1x105 wild-type or transgenic promastigotes in the
right hind footpad. Disease progression was monitored using calipers to measure
footpad thickness. Lesion size was determined as the thickness of the infected
foot minus the thickness of the uninfected foot. Transgenic CD40LE organisms
generated lesions that were comparable to those of wild-type organisms (Figure
17). Lesions contained similar parasite numbers as determined by limiting dilution
assay (Figure 17, inset). These data indicate that the insertion of the transgene does
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Figure 15: Parasite growth curves.
1x106 wild-type, empty vector, or CD40LE parasites were inoculated into 5mL
of 50:50 media. 100µL of culture was harvested at each indicated time point and
metabolic activity was measured using an MTT assay. Growth curves of wild-
type (open circles), pSAT (gray circes), and CD40LE organisms (closed circles)
were compared (Mean±SD). There were no differences observed among the growth
curves.
74
Figure 16: Infection of BMMφ with L. major, L. major pSAT, and L. major
CD40LE.
BMMφ were infected for 2 hr with wild-type (A), empty vector (B), or CD40LE
(C) promastigotes and stained with anti-L. major serum to visualize parasites. Pro-
pidium iodide was used to counterstain the nucleus. Results are representative of at
least three experiments. No differences among samples were observed.
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Table 2: Two hour infection of BMMφ with wild-type or transgenic parasites.
Total number of
macrophages
Number of Infected Total number infected with >3
macrophages macrophages of parasites parasites
L. major 100 90a±7.18b 327±81.67 58±15.57
L. major
CD40LE 100 87±7.09 327±58.99 58±13.03
13.2
aMean from 5 independent experiments.
bStandard Deviation.
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Figure 17: CD40LE parasites cause lesions in SCID mice.
SCID mice on a BALB/c background were infected with 1x105 parasites in the
right hind footpad. Lesion size was monitored, and parasite burdens were deter-
mined at the completion of the experiment (inset). Wild-type (open circles/bars)
and CD40LE organisms (filled circles/bars) induced comparable lesions with simi-
lar numbers of parasites within them.
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not affect parasite viability, nor does it affect their ability to infect and replicate in
immuno-compromised hosts.
Transgenic Leishmania major CD40LE delay lesion development in suscep-
tible BALB/c mice.
To examine whether or not L. major CD40LE had an effect on disease outcome,
BALB/c mice were infected with 1x105 wild-type, pSAT, or CD40LE 13.2 L. ma-
jor parasites in the hind footpad. Lesion size was monitored over the course of the
next 6 weeks. BALB/c mice are susceptible to L. major infections, and therefore
mice infected with wild-type organisms developed large lesions (Figures 18A and
19A). Littermate mice infected with L. major CD40LE 13.2 developed significantly
smaller lesions (Figures 18A and 19A) with fewer parasites within the lesions (Fig-
ure 18B). Dissemination to the lymph nodes was also reduced (Figures 18C and
19B). Mice infected with CD40L parasites exhibited reduced splenomegaly (Fig-
ure 19C) and parasites were virtually undetectable in the spleen of animals receiv-
ing CD40LE expressing organisms (Figure 18D). Mice infected with empty vector
organisms developed lesions comparable to those of mice infected with wild-type
organisms. These data indicate that L. major CD40LE 13.2 parasites are less viru-
lent than wild-type organisms in the susceptible BALB/c host.
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Figure 18: CD40LE parasites exhibit delayed pathology in BALB/c mice.
BALB/c mice were infected in the hind footpad with 1x105 L. major (open cir-
cles/bars), L. major pSAT (gray circles/bars), or L. major CD40LE 13.2 (black
circles/bars). A) Lesion development was measured with calipers twice weekly. B-
D) Parasite burdens were determined in the footpad (B), popliteal lymph node (C),
and spleen (D) at the end of the infection. Results are compiled from 3 independent
experiments, with a minimum of 5 mice per goup, and are expressed as the mean ±
SEM. Asterisks indicate significance (*p<0.05, **p<0.01).
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Figure 19: Disease outcome in BALB/c mice.
BALB/c mice were infected with 1x105 L. major (1), L. major pSAT (2), or L.
major CD40LE (3). Six weeks later, mice were sacrificed, and photos were taken
of footpad lesions (A), popliteal draining lymph nodes (B), and spleens (C). Mice
infected with CD40LE parasites had much smaller lesions, lymph nodes (although
lymph nodes were enlarged compared to uninfected), and spleens than those mice
infected with either wild-type or pSAT organisms.
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Transgenic parasites fail to directly activate macrophages in vitro (data not
shown).
We examined biological roles for CD40L in vitro utilizing a variety of tech-
niques. First, bone marrow derived macrophages were infected for 45 minutes
with either wild-type or transgenic parasites and NF-κB translocation was observed
through immunofluorescence. Macrophages stimulated for 45 minutes with LPS
were used as a positive control. Neither wild-type or transgenic parasites showed
evidence of NF-κB translocation into the nucleus, although translocation was read-
ily observed in macrophages treated with LPS. These data suggest that transgenic
parasites, like wild-type parasites fail to activate NF-κB translocation.
We examined the ability of macrophages to produce IL-12, TNF-α, and nitric
oxide because CD40L is known to be a potent inducer of IL-12 and play a role
in TNF-α and NO activation. Macrophages were infected for 24 hours with wild-
type or transgenic parasites and supernatants were harvested and assayed for IL-12,
TNF-α, and NO production. Macrophages stimulated with LPS or L929 cells ex-
pressing CD40L induced IL-12, although only LPS induced measurable levels of
TNF-α and NO. Macrophages infected with either wild-type or transgenic parasites
failed to induce measurable levels of IL-12, TNF-α, or NO. When wild-type L. ma-
jor were added to L929 cells expressing CD40L and used to stimulate macrophages,
IL-12 induction was abrogated. These data taken together suggest that the ability of
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the parasite to actively suppress IL-12 production overrides the CD40L stimulation
provided by the transgenic parasite in this in vitro experiment.
We also measured the level of CD40 present on the surface of infected macrophages
to detect any up-regulation of this co-stimulatory molecule in response to infection
with transgenic parasites. Similar to wild-type parasites, transgenic parasites fail to
induce CD40 up-regulation on infected macrophages. Stimulation with LPS was
used as a positive control, and 91% up-regulation of CD40 was observed on these
macrophages compared to 1% on infected macrophages.
The transgenic parasites appear not to directly activate macrophages, but are
clearly playing a role in vivo. To determine if interaction with T cells was required,
we examined the ability of macrophages infected with transgenic parasites to affect
T cell proliferation. Macrophages were infected with either wild-type or transgenic
parasites and concurrently given ovalbumin. Approximately three hours later, CFSE
labeled DO11.10 T cells were added for 96 hours and T cell proliferation was mea-
sured by flow cytometry. Macrophages infected with transgenic parasites induced
robust T cell proliferation, while macrophages infected with wild-type parasites in-
duced no proliferation above background. These data suggest that parasite derived
CD40L may act to improve antigen presentation, or that T cells may be required for
the effects of parasite derived CD40L to be observed in vitro.
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Transgenic parasites induce lower levels of the Th2 cytokine IL-4 in suscep-
tible hosts.
To examine cytokine induction from draining lymph nodes ex vivo, we used the
ear model of infection, and isolated mRNA from lymph nodes. Disease progression
was monitored using calipers, and lesion size was determined as the diameter of the
ear lesion. As in the footpad model, wild-type L major caused large, non-healing le-
sions (Figure 20, open circles), whereas transgenic organisms induced significantly
smaller lesions (Figure 20, filled circles). At week four post-infection, draining
lymph nodes were harvested directly into trizol to assay in vivo cytokine mRNA
levels (Figure 21A-C). Cytokine mRNA levels were determined using real-time
PCR and normalized to HPRT. Data are expressed as relative fold changes when
compared to uninfected lymph nodes, which were normalized to 1. The transgenic
parasites induced significantly less IL-4 than wild-type parasites (p<0.05) (Figure
21A). In three separate experiments, IL-4 levels were significantly lower in the
nodes of transgenic infected mice relative to wild-type infected mice. IL-10 tran-
scripts in the two groups were also compared. In two of three experiments, IL-10
levels were also reduced in the transgenic infected mice (p<0.05), but when the
three experiments were compiled and compared to wild-type, the differences were
not significant (Figure 21B). Wild-type and transgenic parasites induced compara-
ble levels of IFN-γ (Figure 21C).
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Figure 20: BALB/c mice infected in the ear with wild-type or transgenic parasites.
BALB/c mice were infected in the ear dermis with 1x104 promastigotes. Lesion
progression was followed by measuring lesion diameter with calipers. L. major
(open circles) induce large, non-healing lesions. CD40LE organisms (filled cir-
cles) induce smaller lesions in this low dose model. Asterisks indicate significance
(*p<0.05, **p<0.01). Data are compiled from three independent experiments and
are expressed as the mean ± SEM.
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Figure 21: L. major CD40LE induce lower levels of IL-4 in BALB/c lymph nodes.
BALB/c mice were infected in the ear dermis with 1x104 promastigotes. A) IL-4,
B) IL-10, and C) IFN-γ levels were assayed by real-time PCR at week four post-
infection. Asterisk indicates significantly less IL-4 (p<0.05) induced in response to
transgenic relative to wild-type infection. Data were normalized to HPRT and are
expressed as fold change relative to uninfected controls. Data are compiled from
three independent experiments and are expressed as the mean ±SEM.
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Parasite derived CD40L is biologically active
To determine if the parasite derived CD40L was active, we infected CD40L-/-
mice on a C57BL/6 background with 1x105 wild-type or transgenic organisms. Le-
sion development was monitored over the course of the next six weeks. C57BL/6
mice lacking CD40L were relatively susceptible to L. major infection, and de-
veloped progressive lesions (Figure 22, open circles). Mice infected with trans-
genic organisms developed significantly smaller lesions (p<0.01), indicating that
the CD40L produced by the parasite was biologically active in vivo.
We also examined disease progression in CD40-/- mice on a C57BL/6 back-
ground to confirm that the attenuated phenotype was due to parasite derived CD40L.
We would expect that parasites expressing CD40L would have no phenotype in
mice lacking CD40, and that is what we observed. CD40-/- mice infected with
transgenic parasites developed lesions that were similar in size to those caused by
wild-type parasites (Figure 23). These lesions contained comparable numbers of
parasites as determined by limiting dilution assay (Figure 23, inset). Taken to-
gether, these data suggest that parasite derived CD40L is biologically active and
responsible for the attenuated phenotype observed.
As a control for these experiments, wild-type C57BL/6 mice were infected with
5x105 wild-type or transgenic parasites (Figure 24). Mice infected with transgenic
parasites developed significantly smaller lesions than those infected with wild-type
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Figure 22: L. major CD40LE cause smaller lesions in CD40L-/- mice.
CD40L-/- mice on a C57BL/6 background were infected with 1x105 wild-type
(open circles/bars) or transgenic (filled circles/bars) parasites. Mice infected with
wild-type parasites developed large lesions, while those infected with transgenic
parasites developed smaller lesions with fewer parasites. Asterisks indicate signifi-
cance (**p<0.01).
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Figure 23: Transgenic parasites cause lesions in C57BL/6 CD40KO mice.
CD40-/- mice on a C57BL/6 background were infected with 5x105 wild-type (open
circles) or transgenic parasites (filled circles). Disease progression was monitored
and parasite burdens were determined at the end of the experiment (inset). Mice
infected with transgenic parasites developed lesions comparable to those in mice in-
fected with wild-type parasites, with comparable numbers of parasites within them.
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Figure 24: L. major CD40LE reduce disease in C57BL/6 mice.
C57BL/6 mice were infected with 5x105 wild-type or transgenic parasites in the
right hind footpad. Disease progression was monitored. Wild-type infected mice
(open circles) developed small lesions that plateaued around 4-5 weeks post-
infection. Infection with transgenic parasites (filled circles) resulted in smaller le-
sions that also plateaued at 4-5 weeks post infection. Asterisks indicate significance
(*p<0.05, **p<0.01). Data are compiled from three independent experiments and
are expressed as the mean ± SEM.
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organisms (Figure 24). However, this phenotype was less dramatic that that ob-
served in the CD40L-/- and BALB/c mice.
Live L. major CD40LE organisms establish protection against challenge with
wild-type organisms
We examined the ability of the transgenic organisms to protect in a vaccination
model of leishmaniasis. For these studies, the resistant C57BL/6 strain of mice was
used. Several groups have demonstrated that these mice resolve infection with wild-
type parasites and develop immunity to reinfection [117, 158]. C57BL/6 mice were
infected with a low dose (5x104) of either wild-type L. major, L. major pSAT, or
L. major CD40LE 13.2 in the right hind footpad. Four to five weeks following ini-
tial infection, mice were re-challenged with 5x105 wild-type L. major parasites in
the contralateral footpad and disease progression was monitored as above. As pre-
viously reported, mice that had cleared an infection with wild-type parasites were
resistant to re-infection (Figure 25)[159]. Mice that were previously infected with
transgenic parasites were similarly protected from re-infection. Mice that were not
previously infected developed larger lesions with higher parasite numbers within
them (Figure 25 inset). These data suggest that the attenuated transgenic organisms
retain the immunogenicity of their wild-type counterparts.
Next we wanted to ascertain if the transgenic parasite would be able to provide
protection to the susceptible BALB/c mouse. Vaccination with viable wild-type
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Figure 25: L. major CD40LE 13.2 induce protection against wild-type challenge
in C57BL/6 mice.
C57BL/6 mice were infected with 5x104 L. major (open circles/bars), L. major
pSAT (gray circles/bars), or L. major CD40LE 13.2 organisms (black circles/bars)
in the right hind footpad. Lesions were allowed to heal, and then mice were chal-
lenged in the contralateral footpad with 5x105 wild-type parasites. Lesion develop-
ment was monitored and burdens determined as previously described. A group of
unprotected mice was used as a control for lesion development (hatched lines/bars).
Asterisks indicate significantly larger (p<0.05) lesions in unprotected mice when
compared to any protected group. Results are compiled from three independent
experiments and are expressed as the mean ± SEM.
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organisms is not possible in this model, because BALB/c mice develop large, non-
healing lesions and eventually succumb to infection. BALB/c mice were infected
with a low dose (5x104) of CD40LE 13.2 organisms in the right hind footpad. Four
to five weeks later, mice were re-challenged with 1x105 wild-type L. major pro-
mastigotes in the contralateral footpad, and lesions were monitored. Vaccination
of susceptible BALB/c mice with L. major CD40LE 13.2 resulted in a significant,
albeit modest, reduction of lesion size in challenged animals (Figure 26, filled cir-
cles). These lesions contained approximately one log fewer parasites than unvac-
cinated animals (Figure 26 inset), indicating that vaccination with the transgenic
organism was unable to completely overcome the Th2 bias in these animals and
induce full protection.
Summary
In summary, we have generated transgenic Leishmania major parasites that ex-
press CD40L mRNA and protein at both life stages. By all criteria, transgenic
parasites appear to be as healthy as wild-type organisms. Parasites induce signif-
icantly smaller lesions in the susceptible BALB/c mouse model, and induce less
IL-4 in this model of infection. Infection of CD40L deficient mice and CD40 de-
ficient mice suggest that attenuated phenotypes are due to parasite derived CD40L.
In addition, transgenic parasites are able to provide full protection in the resistant
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Figure 26: Protection with transgenic parasites in BALB/c mice.
BALB/c mice were injected with 5x104 transgenic parasites (black circles/bars),
and four to five weeks later were challenged with 1x105 wild-type parasites. Un-
protected mice were used as a control for lesion development (hatched lines/bars).
Inset shows parasite burden. Asterisks indicate significance (*p<0.05, **p<0.01).
Results are representative of three independent experiments.
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Leishmaniasis is a disease that is endemic in nations with populations that can-
not easily afford the costly drugs used to treat it. An effective vaccine is needed to
prevent infection and improve the quality of life for at-risk people. As mentioned
previously, leishmanization can provide powerful immunity against infection [100],
but is not routinely practiced due to the incidence of lesions requiring treatment and
the potential for secondary infections. Many vaccine strategies have been examined
to improve upon traditional leishmanization, including using killed parasites with
adjuvants [101] and generating attenuated strains [137–139, 141, 142]. Attenuated
strains have shown some success in animal models, but thus far none have been suc-
cessfully transferred to the clinic. One major challenge with attenuation was that
some strains lost immunogenicity during attenuation [144, 145]. Our approach was
to develop a transgenic parasite that would express a co-stimulatory molecule. We
hypothesized that the transgenic organisms would induce less pathology in suscep-
tible mice and would provide protection against re-challenge with wild-type organ-
isms. Our goal was to develop an attenuated organism that would retain immuno-
genicity and thus be an improved alternative to traditional leishmanization.
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We chose to use the co-stimulatory molecule CD40L for this study for a num-
ber of reasons. CD40L is known to be important for T cell activation and antigen
presentation through binding its receptor, CD40. It has been shown to play an im-
portant role in cell mediated immunity, and has been demonstrated in a number of
studies to be relevant in leishmanial infection [84, 147, 148]. Mice lacking either
CD40 or CD40L have been shown to be more susceptible to infection with Leish-
mania spp. [84, 146–148]. Previously, we have shown that combining CD40L with
leishmanial antigens can improve disease outcome in susceptible animal models
[151]. Also, vaccination with CD40 ligand trimer DNA was shown to provide pro-
tection in the BALB/c host [152]. Thus in this study we have developed transgenic
L. major organisms expressing the extracellular domain of CD40L.
Our parasites were shown to express CD40L mRNA and protein, and secrete
CD40L into the media. Parasite derived CD40L was demonstrated to form trimers,
required for biological activity. CD40LE expression was detected by both western
blot (data not shown) and ELISA (Figure 13) in parasites isolated from footpads of
mice infected for six weeks, indicating a stable level of expression. Using a variety
of methods, we examined whether this insertion had any effect on the fitness of the
organism. By all criteria, the transgenic organisms appear to be as healthy as wild-
type organisms. The growth curves for these organisms were virtually identical,
and parasites were able to infect macrophages and convert into the amastigote form
within equally well. In addition, infection of SCID mice with transgenic parasites
resulted in lesions comparable in size to wild-type infected mice with similar num-
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bers of parasites within them (Figure 17). From these data, we conclude that the
insertion of transgenic DNA into the parasite genome has no discernable effect on
the growth and infectivity of the parasite.
The question of how the CD40L secreted by the parasite is able to access CD40
positive cells remains unanswered. We provide evidence that some CD40L is re-
leased from monolayers of infected cells (Figure 12), but we have not formally
determined whether it was secreted from these cells or released upon parasite de-
struction of the monolayer. Previous work in our lab demonstrated that MCP-1
secreted by transgenic parasites was unable to escape the macrophage until the cell
was lysed [154]. Our observations that some CD40L was released from infected
macrophages is consistent with the work of Dumas et al. who developed L. ma-
jor secreting GM-CSF and reported 25% escape of GM-CSF from the macrophage
[160]. Further studies must be done to determine the extent and mechanism of
CD40L release from infected macrophages.
One major concern when using a genetically modified organism is the potential
for revertants. Our data from parasites retrieved from infected footpads would sug-
gest stable integration of CD40L into the genome, and the constant expression level
over time would suggest little loss of expression. However, we cannot guarantee
that no revertants exist. We would suggest for future development of this organism
combining CD40L expression with defined gene knockout organisms, such as the
lpg2 mutant. This would take advantage of the attenuated lpg2 parasite, and add
the co-stimulation of the CD40L molecule. Combination of the different genetic
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manipulations may lower the incidence of revertants to virulent forms due to ir-
reversible genome changes and increase efficacy of the vaccine through improved
immunogenicity.
We examined the ability of transgenic parasites to influence disease outcome
in the susceptible BALB/c mouse. We found that L. major CD40LE caused sub-
stantially delayed disease in this model of infection. These animals developed sig-
nificantly smaller lesions than those infected with either wild-type or empty vector
organisms. It is important to note that mice infected with empty vector organisms
developed lesions comparable to those of mice infected with wild-type organisms.
This is another indication that the insertion of pSAT into the genome has no effect
on the fitness of the organism. Thus, we conclude that transgenic organisms ex-
pressing CD40L are less virulent that wild-type organisms in a susceptible BALB/c
mouse model.
We wanted to determine a possible explanation for the improved disease pro-
gression in BALB/c mice. We examined possible biological roles for parasite de-
rived CD40L using a variety of in vitro methods (data not shown). Since CD40L
is known to be an inducer of IL-12 from macrophages [43], and plays a role in
the induction of TNF-α and NO, the ability of transgenic parasites to stimulate IL-
12, TNF-α, and NO production from macrophages was tested. While macrophages
stimulated with L929 cells expressing CD40L produced IL-12, infection with trans-
genic parasites failed to induce macrophage IL-12 production. In addition, macrophages
infected with wild-type or transgenic parasites failed to activate TNF-α or NO pro-
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duction. It is well known that wild-type parasites actively suppress IL-12 produc-
tion [111, 114], and we demonstrated that when wild-type parasites were added to
CD40L expressing L929 cells, IL-12 induction was abrogated. These data suggest
that the supression of IL-12 by Leishmania can override the induction signal from
CD40L and the suppression likely occurs downstream of CD40. CD40L induced
IL-12 is mediated by the transcription factor NF-κB, thus the ability of the par-
asite to induce NF-κB translocation was examined. Transgenic parasites, similar
to wild-type parasites, fail to activate NF-κB translocation. The ability of trans-
genic parasites to induce the up-regulation of CD40, the receptor for CD40L on
the macrophage surface was also examined. Infection with wild-type parasites does
not induce CD40 up-regulation. Macrophages infected with transgenic parasites
also failed to up-regulate CD40. Although the BALB/c in vivo results suggest that
parasite derived CD40L plays a role in decreased parasite virulence, no indcations
of direct macrophage activation were observed in these in vitro experiments. There
are several possible explanations for these results. First, transgenic parasites may
not have secreted enough CD40L during in vitro incubation times for macrophage
activation to be detected. Parasites are typically washed prior to infection, which
effectively removed any CD40L present in the culture. L929 cells express mem-
brane bound CD40L, and this expression would not be affected by washing of the
cells, thus CD40L would be present immediately in this method of stimulation. In
contrast, transgenic parasites would have to produce and secrete CD40L before ac-
tivation effects could be observed, and the 45 minute to 24 hour in vitro incubation
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times may not have been long enough for parasite derived CD40L to be produced
in sufficient quantities to measure macrophage activation. In vivo, however, para-
sites would have time to express and secrete CD40L and induce local macrophage
activation over time. This could explain why parasites are able to show an atten-
uated phenotype in vivo while direct activation of macrophages is not observed in
vitro. Another possibility is that the assays used to detect macrophage activation
were not sensitive enough to detect subtle changes induced by transgenic parasites.
Real-time PCR for cytokine mRNA from infected macrophages may have been a
more sensitive measure than measurement of protein in supernatant by ELISA. In
addition, the unknown mechanism of CD40L could have played a role in the inabil-
ity of in vitro assays to detect macrophage activation. If CD40L must be released
through lysis of infected macrophages, longer incubation times would be required
to allow parasites to replicate enough to induce macrophage lysis. Alternatively, in-
fected macrophages could be lysed and used as a stimulation for other macrophages
to determine if CD40L from infected macrophages would induce activation.
It is also possible that transgenic parasites did not directly activate macrophages.
It is unlikely that parasite derived CD40L had no effect on macrophages, because
such dramatic phenotypes in BALB/c mice are observed, but other cells may be
required to assist CD40L macrophage activation. This hypothesis is supported by
our studies in SCID mice. If parasite derived CD40L alone could fully activate
macrophages to kill parasites, we would have expected to see a phenotype in these
mice. SCID mice lack B and T cells, and we observe no difference in phenotype for
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transgenic parasite when compared to the wild-type parasite in this model, which
would suggest that adaptive immunity is required for parasite derived CD40L to
show an effect. In addition, in vitro studies using macrophages as antigen present-
ing cells to DO11.10 T cells showed that macrophages infected with transgenic
parasites were able to induce robust T cell proliferation of naı̈ve T cells, while
macrophages infected with wild-type organisms were unable to induce T cell prolif-
eration. These data would suggest that parasite derived CD40L may have an effect
on improved antigen presentation, or that T cell help is also required for CD40L to
be most effective.
Because the phenotype in BALB/c mice was so dramatic, and the in vitro data
suggest that macrophage interaction with T cells may be required to observe the
effects of parasite derived CD40L, we examined in vivo cytokine mRNA levels in
draining lymph nodes from lesions. We hypothesized that looking directly at in-
fected lymph nodes would provide insight into the observed phenotype that was
lacking with the in vitro experiments. We found that the wild-type organisms were
better inducers of the anti-inflammatory cytokine IL-4 in BALB/c mice. Transgenic
organisms induced a significantly lower level of this cytokine. This appeared to be
specific to IL-4 because IFN-γ levels were not significantly altered. We also ob-
served a trend toward reduced IL-10 induction in transgenic infected animals. In
two of three independent experiments, transgenic infected animals induced signif-
icantly lower levels of IL-10, but when the three experiments were compiled, this
difference was no longer significant. It is well known that in BALB/c mice, IL-4
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and IL-10 are induced following infection with L. major [118, 161]. In the resistant
C57BL/6 strain of mice, however, IFN-γ is the dominant cytokine that is produced
in response to this infection [43, 159, 161]. IL-4 is thought to be a major contributor
in the generation of a detrimental Th2 response in BALB/c animals, and treatment
with anti-IL-4 antibody early in infection can confer a resistant phenotype on these
genetically susceptible animals [118, 162, 163]. In addition, BALB/c mice defi-
cient in the IL-4 gene are resistant to L. major infection [121]. Notably, in these
models a converse increase in IFN-γ was not observed, which would suggest that
for BALB/c animals, interfering with the Th2 response is sufficient to improve dis-
ease outcome. The decreased lesion induction by the transgenic parasites correlates
with the decrease in IL-4 production that occurs. We conclude that these data taken
in the context of the literature provide a plausible explanation for the attenuated
phenotype observed in this model of infection.
We also examined disease progression in the resistant C57BL/6 strain of mice.
Mice infected with transgenic parasites developed slightly smaller lesions than
wild-type infected animals, indicating that these parasites can have a modest ef-
fect on disease outcome in this resistant strain, however this phenotype is less dra-
matic than that observed in the susceptible mouse model. If the mechanism of
action of the transgenic parasite is to reduce Th2 cytokines, this is not unexpected,
as C57BL/6 mice preferentially mount a Th1 response to Leishmania, and express
lower levels of IL-4 than susceptible BALB/c animals.
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Many groups have shown that disruption of CD40-CD40L interactions results in
susceptibility in the otherwise resistant C57BL/6 mouse [84, 146–148]. To confirm
that parasite derived CD40L was active, we infected CD40L-/- and CD40-/- mice on
a C57BL/6 background with wild-type or transgenic parasites. In CD40L-/- mice,
transgenic parasites caused reduced disease. Transgenic infected mice developed
significantly smaller lesions with fewer parasites than mice infected with wild-type
organisms. From these data, we conclude that the CD40L produced by the parasite
was biologically active, and provided complementation for the CD40L deficiency in
these animals. In CD40 deficient mice, the opposite occurred. Transgenic parasites
induced progressive disease with lesions at least as large as those observed in mice
infected with wild-type parasites. These data suggest that parasite derived CD40L
is responsible for the attenuation seen in wild-type C57BL/6 mice and that it signals
through host CD40.
We also examined the ability of the transgenic organism to vaccinate C57BL/6
mice. Animals that were vaccinated with wild-type or transgenic organisms were
equally protected against re-challenge, indicating that these organisms, although re-
duced in virulence, retain immunogenicity required to induce an adaptive immune
response. Previous studies in our laboratory demonstrated that combining L929
cells expressing CD40L with parasite antigens was able to provide significant pro-
tection in the susceptible BALB/c mouse [151]. Also, CD40L trimer DNA has been
used successfully to vaccinate BALB/c mice against L. major [152]. Therefore, we
hypothesized that the CD40LE organism would be able to provide protection in the
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BALB/c model. We found that immunization with transgenic L. major CD40LE
was able to induce partial protection in susceptible BALB/c mice, with vaccinated
animals developing slightly, but significantly smaller lesions. This suggests that
CD40L expressing organisms were unable to overcome the overwhelming Th2 bias
in these animals to provide complete protection against wild-type challenge. The
differences seen in our study when compared to those mentioned above may be
explained by differences in study design. In our previous study, transfected cells
expressing CD40L were mixed with soluble Leishmania antigen (SLA) and mice
were vaccinated three times prior to challenge with wild-type organisms. The trans-
genic parasites in the present study make relatively small amounts of CD40L com-
pared to these previous doses. If the expression level of CD40L were increased, we
would expect improved protection in BALB/c mice.
Others have attempted to generate transgenic “suicide” Leishmania organisms
with varying degrees of success. Tobin et al. generated L. major expressing IFN-γ
[164]. These parasites were able to delay lesion development in nude mice, but had
no effect on disease outcome in BALB/c animals [164]. Dumas et al. developed
GM-CSF secreting organisms with more success [160]. These parasites were able
to delay lesion development in BALB/c animals and there was evidence that GM-
CSF could be combined with traditional treatments to improve disease outcome
[160]. However, this group did not examine the protective capabilities of the GM-
CSF secreting organism. The L. major organisms we have developed expand upon
these previous studies generating transgenic Leishmania spp. to manipulate disease
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outcome. To our knowledge, this is the first report of the development of a trans-
genic Leishmania major to produce a murine co-stimulatory molecule. Our data
correlate well with data obtained by Chamekh et al. that showed that Trypanosoma
cruzi transfected with CD40L are able to reduce disease and induce protection in
an animal model [165]. Our data confirm the ability of CD40L to act as an adju-
vant to generate an attenuated organism that can induce a protective response in the
host. Thus this method of generating less virulent organisms using host immune-
stimulatory molecules can have merit in a variety of infections.
In summary, previous observations that CD40L could improve disease outcome
and provide protection in leishmaniasis led us to develop transgenic organisms se-
creting the extracellular domain of this protein. We observed that these transgenic
organisms are less virulent than wild-type organisms, while retaining immuno-
genicity to induce a protective response. We conclude that transgenic parasites
expressing immune-stimulatory molecules may provide a better alternative to tradi-
tional leishmanization resulting in improved vaccines.
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